{"content":"<li class=\"n-box-item date-title\" data-end=\"1546577999\" data-start=\"1546491600\" data-txt=\"Monday, December 23, 2019\">Thursday, January  3, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3420558\" data-ts=\"1546556984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCII\" target=\"_blank\">RCII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420558-rent-centerminus-2-judge-favors-restraining-order-for-vintage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rent-A-Center -2% as judge favors restraining order for Vintage</a></h4><ul>   <li>Judge Sam Glasscock III says he expects to grant a temporary restraining order to Vintage Capital later this week, with Rent-A-Center (NASDAQ:<a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a>) trying to pull out of a $1.37B acquisition deal, Bloomberg reports.</li>    <li>He's expecting a one- or two-day trial on the matter to come next month.</li>    <li>Vintage sued in December after Rent-A-Center attempted to <a href=\"https://seekingalpha.com/news/3417782-rent-center-pulls-merger\" target=\"_blank\">pull out of the deal</a> amid concerns the deal couldn't reliably close.</li>    <li><a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a> is <font color=\"red\">down 2%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420558\" data-linked=\"Rent-A-Center -2% as judge favors restraining order for Vintage\" data-tweet=\"$RCII - Rent-A-Center -2% as judge favors restraining order for Vintage https://seekingalpha.com/news/3420558-rent-centerminus-2-judge-favors-restraining-order-for-vintage?source=tweet\" data-url=\"https://seekingalpha.com/news/3420558-rent-centerminus-2-judge-favors-restraining-order-for-vintage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420553\" data-ts=\"1546555350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMID\" target=\"_blank\">AMID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420553-amid-swn-flxn-and-cmi-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMID, SWN, FLXN and CMI among notable after hour movers</a></h4><ul><li><b>Top Gainers: </b><a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a> <font color=\"green\">+24.4%</font>. <a href='https://seekingalpha.com/symbol/RECN' title='Resources Connection, Inc.'>RECN</a> <font color=\"green\">+11.7%</font>.<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a> <font color=\"green\">+9.3%</font>. <a href='https://seekingalpha.com/symbol/SIGA' title='SIGA Technologies Inc.'>SIGA</a> <font color=\"green\">+3.9%</font>. <a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Co.'>SWN</a> <font color=\"green\">+3%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color=\"red\">-3.9%</font>. <a href='https://seekingalpha.com/symbol/TAK' title='Takeda Pharmaceutical Co., Ltd. ADR'>TAK</a> <font color=\"red\">-2.1%</font>. <a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color=\"red\">-1.8%</font>. <a href='https://seekingalpha.com/symbol/CMI' title='Cummins Inc.'>CMI</a> <font color=\"red\">-1.6%</font>. <a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color=\"red\">-1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420553\" data-linked=\"AMID, SWN, FLXN and CMI among notable after hour movers\" data-tweet=\"$AMID $AMID $RECN - AMID, SWN, FLXN and CMI among notable after hour movers https://seekingalpha.com/news/3420553-amid-swn-flxn-and-cmi-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420553-amid-swn-flxn-and-cmi-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420534\" data-ts=\"1546551529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RETA\" target=\"_blank\">RETA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420534-reata-pharma-on-go-late-stage-study-of-bardoxolone-in-adpkd-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reata Pharma on go with late-stage study of bardoxolone in ADPKD; shares up 2% after hours</a></h4><ul><li>Reata Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a>) is up <font color=\"green\">2%</font> after hours following its <a href=\"https://seekingalpha.com/pr/17370083-reata-announces-clinical-trial-design-falcon-phase-3-trial-bardoxolone-methyl-treatment\" target=\"_blank\">announcement </a>of the design of a Phase 3 clinical trial, FALCON, evaluating bardoxolone methyl in patients with autosomal dominant polycystic kidney disease &#40;ADPKD&#41;.</li><li>The randomized, double-blind, placebo-controlled study will enroll ~300 subjects. The primary endpoint will be the change from baseline in estimated glomerular filtration rate (a measure of kidney function) after 48 weeks of treatment and a four-week withdrawal period compared to control.</li><li>The trial should commence mid-year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420534\" data-linked=\"Reata Pharma on go with late-stage study of bardoxolone in ADPKD; shares up 2% after hours\" data-tweet=\"$RETA - Reata Pharma on go with late-stage study of bardoxolone in ADPKD; shares up 2% after hours https://seekingalpha.com/news/3420534-reata-pharma-on-go-late-stage-study-of-bardoxolone-in-adpkd-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3420534-reata-pharma-on-go-late-stage-study-of-bardoxolone-in-adpkd-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420522\" data-ts=\"1546550496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVAX\" target=\"_blank\">NVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420522-novavax-up-10-after-hours-on-positive-nanoflu-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novavax up 10% after hours on positive NanoFlu data</a></h4><ul><li>Novavax (NASDAQ:<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>) is up <font color=\"green\">10%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17370120-novavax-announces-positive-phase-2-nanoflu-results-older-adults\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial evaluating a range of formulations of flu vaccine NanoFlu with and without the Matrix-M adjuvant.</li><li>All formulations were well-tolerated and induced \"vigorous\" immune responses to the four strains in the vaccine.</li><li>Matrix-M adjuvant elicited significantly enhanced immune responses compared to unadjuvanted vaccine.</li><li>A Phase 3 study is next up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420522\" data-linked=\"Novavax up 10% after hours on positive NanoFlu data\" data-tweet=\"$NVAX - Novavax up 10% after hours on positive NanoFlu data https://seekingalpha.com/news/3420522-novavax-up-10-after-hours-on-positive-nanoflu-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3420522-novavax-up-10-after-hours-on-positive-nanoflu-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>61&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420510\" data-ts=\"1546549693\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420510-flexion-q4-revenue-up-36-shares-down-19-after-hours-on-zilretta-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flexion Q4 revenue up 36%; shares down 19% after hours on Zilretta outlook</a></h4><ul><li>On a preliminary basis, Flexion Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a>) generated $9.5M in <a href=\"https://seekingalpha.com/pr/17370090-flexion-therapeutics-announces-preliminary-unaudited-fourth-quarter-full-year-2018-revenue\" target=\"_blank\">revenue </a>in Q4, up 36% yoy. Full-year revenue was ~$22.5M.</li><li>The company expects ZILRETTA (triamcinolone acetonide) sales this year of $65M - 80M.</li><li>Management will host a conference call tomorrow, January 4, at 8:30 am ET to discuss the results and outlook.</li><li>Shares are down <font color=\"red\">19%</font> after hours in apparent reaction to its ZILRETTA outlook.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420510\" data-linked=\"Flexion Q4 revenue up 36%; shares down 19% after hours on Zilretta outlook\" data-tweet=\"$FLXN - Flexion Q4 revenue up 36%; shares down 19% after hours on Zilretta outlook https://seekingalpha.com/news/3420510-flexion-q4-revenue-up-36-shares-down-19-after-hours-on-zilretta-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3420510-flexion-q4-revenue-up-36-shares-down-19-after-hours-on-zilretta-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420504\" data-ts=\"1546548374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVA\" target=\"_blank\">AVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420504-idaho-regulator-denies-avista-sale-to-canadian-utility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Idaho regulator denies Avista sale to Canadian utility</a></h4><ul><li>Avista (<a href='https://seekingalpha.com/symbol/AVA' title='Avista Corporation'>AVA</a> <font color='red'>-1.8%</font>) tumbles to a 52-week low on news that the Idaho Public Utilities Commission <a href=\"http://www.spokesman.com/stories/2019/jan/03/idaho-regulators-deny-sale-of-avista-to-canadian-u/\" target=\"_blank\">denied its pending merger</a> with Hydro One (<a href='https://seekingalpha.com/symbol/HRNNF' title='Hydro One Ltd'>OTC:HRNNF</a>).</li><li>The move in Idaho follows similar action <a href=\"https://seekingalpha.com/news/3414843-avistas-5_3b-sale-hydro-one-nixed-washington-state-regulator\" target=\"_blank\">last month</a> by Washington regulators, who also denied the sale.</li><li>The Idaho PUC says the sale is prohibited by state law, which prohibits the transfer of assets from a regulated electric utility to an entity that is \"owned or controlled, directly or indirectly, by... any other state.\"</li><li>Although Hydro One is an investor-owned utility, Canada's Ontario province is its largest shareholder with 47% of outstanding shares, giving it significant control and influence over the utility, the commission says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420504\" data-linked=\"Idaho regulator denies Avista sale to Canadian utility\" data-tweet=\"$AVA $AVA $HRNNF - Idaho regulator denies Avista sale to Canadian utility https://seekingalpha.com/news/3420504-idaho-regulator-denies-avista-sale-to-canadian-utility?source=tweet\" data-url=\"https://seekingalpha.com/news/3420504-idaho-regulator-denies-avista-sale-to-canadian-utility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420501\" data-ts=\"1546547356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOM\" target=\"_blank\">XOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420501-oil-prices-rebound-after-early-slide-surveys-show-declining-output\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil prices rebound after early slide, as surveys show declining output</a></h4><ul><li><a href=\"https://www.reuters.com/article/us-global-oil/oil-rises-in-choppy-trade-as-opec-supply-cuts-vie-with-demand-worry-idUSKCN1OX03W\" target=\"_blank\">Crude oil prices rose</a> for the fourth straight session in volatile trade, boosted by separate surveys that revealed monthly production declines from major producers; February WTI settled <font color=\"green\">+1.2%</font> to $47.09/bbl, while Brent <font color=\"green\">+1.9%</font> at $55.95/bbl.</li><li>OPEC produced 32.68M bbl/day of oil in December, down 460K bbl/day from the previous month, according to a <a href=\"https://www.reuters.com/article/us-oil-opec-survey/opec-oil-output-posts-biggest-drop-since-2017-on-saudi-move-idUSKCN1OX1AN\" target=\"_blank\">Reuters survey</a>, while a survey from Bloomberg showed OPEC output down by 530K bbl/day to 32.6M bbl/day.</li><li>\"Oil is flip-flopping on concerns of supply and demand,\" says Price Futures analyst Phil Flynn. \"It\u2019s really a battle between the supply situation, which looks to be tightening, versus the possibility that demand will drop off.\"</li><li>Today\u2019s \"volatility across risk assets, including energy, is growth related and fears of a slowing global economy continue to be a <a href=\"https://www.marketwatch.com/story/oil-turns-higher-as-supply-relief-offsets-stock-market-drop-2019-01-03\" target=\"_blank\">major headwind</a> on oil from a demand standpoint,\" says Tyler Richey of the <em>Sevens Report</em>.</li><li>\"Oil is due for a bounce as futures are oversold but without a notable catalyst, and a rebound in stocks, it will be hard for WTI to rally beyond resistance in the low $50s,\" Richey adds.</li><li>Most oil and gas stocks trade lower, along with the rest of the equity market: <a href='https://seekingalpha.com/symbol/XOM' title='Exxon Mobil Corporation'>XOM</a> <font color=\"red\">-1.4%</font>, <a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color=\"red\">-1.7%</font>, <a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a> <font color=\"red\">-1.7%</font>, <a href='https://seekingalpha.com/symbol/RDS.B' title='Royal Dutch Shell plc'>RDS.B</a> <font color=\"red\">-0.2%</font>, <a href='https://seekingalpha.com/symbol/BP' title='BP p.l.c.'>BP</a> <font color=\"green\">+0.5%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/GUSH' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3x Shares ETF'>GUSH</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/DRIP' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares ETF'>DRIP</a>, <a href='https://seekingalpha.com/symbol/IEO' title='iShares U.S. Oil & Gas Exploration & Production ETF'>IEO</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/NDP' title='Tortoise Energy Independence Fund'>NDP</a>, <a href='https://seekingalpha.com/symbol/PXE' title='Invesco Dynamic Energy Exploration & Production Portfolio ETF'>PXE</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Invesco S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='Invesco Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a>, <a href='https://seekingalpha.com/symbol/FXN' title='First Trust Energy AlphaDEX ETF'>FXN</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/DDG' title='ProShares Short Oil & Gas ETF'>DDG</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/NANR' title='SPDR S&P North American Natural Resources ETF'>NANR</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a>, <a href='https://seekingalpha.com/symbol/USOU' title='United States 3x Oil Fund'>USOU</a>, <a href='https://seekingalpha.com/symbol/USOD' title='United States 3x Short Oil Fund ETF'>USOD</a>, <a href='https://seekingalpha.com/symbol/FTXN' title='First Trust Nasdaq Oil & Gas ETF'>FTXN</a>, <a href='https://seekingalpha.com/symbol/JHME' title='John Hancock Multifactor Energy ETF'>JHME</a>, <a href='https://seekingalpha.com/symbol/ERYY' title='Direxion Daily Energy Bear 1x Shares ETF'>ERYY</a>, <a href='https://seekingalpha.com/symbol/ERGF' title='iShares Edge MSCI Multifactor Energy ETF'>ERGF</a>, <a href='https://seekingalpha.com/symbol/OILD' title='ProShares UltraPro 3x Short Crude Oil ETF'>OILD</a>, <a href='https://seekingalpha.com/symbol/OILU' title='ProShares UltraPro 3x Crude Oil ETF'>OILU</a>, <a href='https://seekingalpha.com/symbol/USAI' title='American Energy Independence ETF'>USAI</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3420501\" data-linked=\"Oil prices rebound after early slide, as surveys show declining output\" data-tweet=\"$XOM $XOM $CVX - Oil prices rebound after early slide, as surveys show declining output https://seekingalpha.com/news/3420501-oil-prices-rebound-after-early-slide-surveys-show-declining-output?source=tweet\" data-url=\"https://seekingalpha.com/news/3420501-oil-prices-rebound-after-early-slide-surveys-show-declining-output\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420498\" data-ts=\"1546547015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDAP\" target=\"_blank\">EDAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420498-edap-up-21-on-first-u-s-sale-of-focal-one\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EDAP up 21% on first U.S. sale of Focal One</a></h4><ul><li>Thinly traded nano cap EDAP TMS SA (<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a> <font color=\"green\">+20.9%</font>) is up on more than a 4x surge in volume, albeit on turnover of only 241K shares, following its <a href=\"https://seekingalpha.com/pr/17369310-edap-tms-sa-john-wayne-cancer-institute-first-us-medical-center-acquire-edaps-breakthrough\" target=\"_blank\">announcement </a>of the first U.S. sale of its Focal One HIFU device used to treat localized prostate cancer.</li><li>The John Wayne Cancer Institute in Santa Monica, CA acquired the system.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420498\" data-linked=\"EDAP up 21% on first U.S. sale of Focal One\" data-tweet=\"$EDAP - EDAP up 21% on first U.S. sale of Focal One https://seekingalpha.com/news/3420498-edap-up-21-on-first-u-s-sale-of-focal-one?source=tweet\" data-url=\"https://seekingalpha.com/news/3420498-edap-up-21-on-first-u-s-sale-of-focal-one\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420497\" data-ts=\"1546546780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QTWO\" target=\"_blank\">QTWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420497-stephens-bumps-q2-up-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stephens bumps Q2 up to Overweight</a></h4><ul><li>Investment bank Stephens upgrades Q2 Holdings (<a href='https://seekingalpha.com/symbol/QTWO' title='Q2 Holdings, Inc.'>QTWO</a> <font color=\"red\">-1.3%</font>) from Equal-Weight to Overweight and cuts the target by a dollar to $59. (Source: Briefing.com.)</li><li>Q2 shares have pulled back <font color=\"red\">16.7%</font> in the quarter but are up nearly <font color=\"green\">30%</font> in the past year.</li><li>The company reported <a href=\"https://seekingalpha.com/pr/17324754-q2-holdings-inc-announces-third-quarter-2018-financial-results\" target=\"_blank\">strong Q3 results</a> in November and last month <a href=\"https://seekingalpha.com/pr/17346858-q2-holdings-boosts-cross-selling-capabilities-accelerates-digital-onboarding-acquisition-gro\" target=\"_blank\">acquired </a>digital onboarding company Gro Solutions.</li><li>Post updated to correct the price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420497\" data-linked=\"Stephens bumps Q2 up to Overweight\" data-tweet=\"$QTWO - Stephens bumps Q2 up to Overweight https://seekingalpha.com/news/3420497-stephens-bumps-q2-up-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3420497-stephens-bumps-q2-up-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420494\" data-ts=\"1546545660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOXL\" target=\"_blank\">BOXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420494-stm-oled-eman-among-notable-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STM, OLED &amp; EMAN among notable tech movers</a></h4><ul><li><strong>Gainers: </strong>Boxlight (NASDAQ:<a href='https://seekingalpha.com/symbol/BOXL' title='Boxlight'>BOXL</a>) <font color=\"green\">+36%</font>. FTE Networks (NYSEMKT:<a href='https://seekingalpha.com/symbol/FTNW' title='FTE Networks, Inc.'>FTNW</a>) <font color=\"green\">+19%</font>. IZEA Worldwide (NASDAQ:<a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a>) <font color=\"green\">+17%</font>. Park Electrochemical (NYSE:<a href='https://seekingalpha.com/symbol/PKE' title='Park Electrochemical Corporation'>PKE</a>) <font color=\"green\">+13%</font>. OptimizeRx (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRX' title='OptimizeRx Corp.'>OPRX</a>) <font color=\"green\">+10%</font>.</li> <li><strong>Losers: </strong>eMagin (NYSEMKT:<a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a>) <font color=\"red\">-12%</font>. Universal Display (NASDAQ:<a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a>) <font color=\"red\">-13%</font>. STMicroelectronics N.V. (NYSE:<a href='https://seekingalpha.com/symbol/STM' title='STMicroelectronics NV'>STM</a>) <font color=\"red\">-12%</font>. Cool Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a>) <font color=\"red\">-12%</font>. Arlo Technologies (NYSE:<a href='https://seekingalpha.com/symbol/ARLO' title='Arlo Technologies'>ARLO</a>) <font color=\"red\">-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420494\" data-linked=\"STM, OLED &amp; EMAN among notable tech movers\" data-tweet=\"$BOXL $BOXL $FTNW - STM, OLED &amp; EMAN among notable tech movers https://seekingalpha.com/news/3420494-stm-oled-eman-among-notable-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420494-stm-oled-eman-among-notable-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420486\" data-ts=\"1546542822\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420486-albemarleminus-6-berenberg-downgrades-seeing-start-of-fundamental-shift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albemarle -6% as Berenberg downgrades, seeing start of fundamental shift</a></h4><ul><li>Albemarle (<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a> <font color='red'>-6.1%</font>) falls sharply after Berenberg <a href=\"https://thefly.com/thestreet/realmoney/index.php/ALBid2843068/ALB-Berenberg-downgrades-Albemarle-to-Hold-as-governments-pressure-lithium-prices\" target=\"_blank\">downgrades</a> shares to Hold from Buy with a $90 price target, slashed from $130, saying it had not anticipated \"what appears to be a concerted attempt by national governments\" to pressure lithium prices in order to promote local battery production.</li><li>Last month's announcement by state-owned Bolivian miner YLB that it will cooperate with German partner ACI Systems to produce 40 kt of lithium hydroxide from 2022 could mark the start of a fundamental shift in supply, Berenberg's Sebastian Bray says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420486\" data-linked=\"Albemarle -6% as Berenberg downgrades, seeing start of fundamental shift\" data-tweet=\"$ALB - Albemarle -6% as Berenberg downgrades, seeing start of fundamental shift https://seekingalpha.com/news/3420486-albemarleminus-6-berenberg-downgrades-seeing-start-of-fundamental-shift?source=tweet\" data-url=\"https://seekingalpha.com/news/3420486-albemarleminus-6-berenberg-downgrades-seeing-start-of-fundamental-shift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420485\" data-ts=\"1546542536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420485-stocks-return-to-session-lows\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks return to session lows</a></h4><ul><li>A bounce attempt has failed for now, with all of the major averages again <font color=\"red\">down 2% or more</font>.</li><li>There are some pockets of green, including biotech (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='green'>+1.1%</font>), which is benefitting from Celgene's $74B sale to Bristol-Myers, and the utilities (<a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a> <font color='green'>+0.3%</font>). Consumer Staples (<a href='https://seekingalpha.com/symbol/XLP' title='Consumer Staples Select Sector SPDR ETF'>XLP</a> <font color='red'>-0.1%</font>) are also holding up.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420485\" data-linked=\"Stocks return to session lows\" data-tweet=\"$IBB $XLU $XLP - Stocks return to session lows https://seekingalpha.com/news/3420485-stocks-return-to-session-lows?source=tweet\" data-url=\"https://seekingalpha.com/news/3420485-stocks-return-to-session-lows\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420480\" data-ts=\"1546541964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCLP\" target=\"_blank\">CCLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420480-csi-compressco-and-permrock-royalty-trust-among-energy-materials-gainers-platinum-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSI Compressco and PermRock Royalty Trust among Energy/Materials gainers; Platinum Group Metals and Pacific Ethanol among losers</a></h4><ul><li><b>Gainers: </b>CSI Compressco (NASDAQ:<a href='https://seekingalpha.com/symbol/CCLP' title='CSI Compressco LP'>CCLP</a>) <font color=\"green\">+12%</font>. PermRock Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/PRT' title='PermRock Royalty Trust'>PRT</a>) <font color=\"green\">+11%</font>. Rosehill Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a>) <font color=\"green\">+10%</font>. Americas Silver (NYSEMKT:<a href='https://seekingalpha.com/symbol/USAS' title='Americas Silver Corporation'>USAS</a>) <font color=\"green\">+9%</font>. Ossen Innovation (NASDAQ:<a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Platinum Group Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLG' title='Platinum Group Metals Ltd'>PLG</a>) <font color=\"red\">-9%</font>. Pacific Ethanol (NASDAQ:<a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a>) <font color=\"red\">-8%</font>. Versum Materials (NYSE:<a href='https://seekingalpha.com/symbol/VSM' title='Versum Materials'>VSM</a>) <font color=\"red\">-7%</font>. Venator Materials (NYSE:<a href='https://seekingalpha.com/symbol/VNTR' title='Venator Materials'>VNTR</a>) <font color=\"red\">-6%</font>. Eclipse Resources (NYSE:<a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420480\" data-linked=\"CSI Compressco and PermRock Royalty Trust among Energy/Materials gainers; Platinum Group Metals and Pacific Ethanol among losers\" data-tweet=\"$CCLP $CCLP $PRT - CSI Compressco and PermRock Royalty Trust among Energy/Materials gainers; Platinum Group Metals and Pacific Ethanol among losers https://seekingalpha.com/news/3420480-csi-compressco-and-permrock-royalty-trust-among-energy-materials-gainers-platinum-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3420480-csi-compressco-and-permrock-royalty-trust-among-energy-materials-gainers-platinum-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420474\" data-ts=\"1546541026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQST\" target=\"_blank\">AQST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420474-needham-sees-27-upside-in-thermo-fisher-in-todays-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham sees 27% upside in Thermo Fisher in today&#39;s analyst action</a></h4><ul><li>Aquestive Therapeutics (<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics'>AQST</a> <font color='green'>+0.3%</font>) initiated with Buy rating and $14 (97% upside) price target at Lake Street.</li><li>Thermo Fisher Scientific (<a href='https://seekingalpha.com/symbol/TMO' title='Thermo Fisher Scientific Inc.'>TMO</a> <font color='red'>-2.1%</font>) initiated with Strong Buy rating and $271 (27% upside) price target at Needham.</li><li>PerkinElmer (<a href='https://seekingalpha.com/symbol/PKI' title='PerkinElmer, Inc.'>PKI</a> <font color='red'>-3.5%</font>) initiated with Hold rating at Needham.</li><li>NeoGenomics (<a href='https://seekingalpha.com/symbol/NEO' title='NeoGenomics Inc.'>NEO</a> <font color='red'>-3%</font>) initiated with Buy rating and $14 (16% upside) price target at Needham.</li><li>Myriad Genetics (<a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a> <font color='green'>+0.2%</font>) initiated with Strong Buy rating and $36 (25% upside) price target at Needham.</li><li>Genomic Health (<a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a> <font color='green'>+1.3%</font>) initiated with Strong Buy rating and $86 (37% upside) price target at Needham.</li><li>Danaher (<a href='https://seekingalpha.com/symbol/DHR' title='Danaher Corporation'>DHR</a> <font color='red'>-2.5%</font>) initiated with Buy rating and $114 (16% upside) price target at Needham.</li><li>Bruker (<a href='https://seekingalpha.com/symbol/BRKR' title='Bruker Corporation'>BRKR</a> <font color='red'>-3%</font>) initiated with Strong Buy rating and $39 (38% upside) price target at Needham.</li><li>Agilent (<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies Inc.'>A</a> <font color='red'>-2.9%</font>) initiated with Buy rating and $77 (21% upside) price target at Needham.</li><li>WellCare Health Plans (<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a> <font color='red'>-0.8%</font>) upgraded to Outperform at Wolfe Research.</li><li>Gilead Sciences (<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+4.1%</font>) upgraded to Outperform with an $85 (29% upside) price target at Oppenheimer.</li><li>Intricon (<a href='https://seekingalpha.com/symbol/IIN' title='IntriCon Corporation'>IIN</a> <font color='red'>-4.3%</font>) upgraded to Buy with a $44 (79% upside) price target at Dougherty &amp; Co.</li><li>Molina Healthcare (<a href='https://seekingalpha.com/symbol/MOH' title='Molina Healthcare, Inc.'>MOH</a> <font color='red'>-5.6%</font>) downgraded to Peer Perform at Wolfe Research.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420474\" data-linked=\"Needham sees 27% upside in Thermo Fisher in today&#39;s analyst action\" data-tweet=\"$AQST $AQST $TMO - Needham sees 27% upside in Thermo Fisher in today&#39;s analyst action https://seekingalpha.com/news/3420474-needham-sees-27-upside-in-thermo-fisher-in-todays-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3420474-needham-sees-27-upside-in-thermo-fisher-in-todays-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420470\" data-ts=\"1546540048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRL\" target=\"_blank\">CRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420470-contract-research-organizations-in-red-on-bmy-celg-tie-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Contract research organizations in the red on BMY/CELG tie-up</a></h4><ul><li>The broad market's bearish mood notwithstanding, contract research organizations (CROs) Charles River Laboratories (<a href='https://seekingalpha.com/symbol/CRL' title='Charles River Laboratories International, Inc.'>CRL</a> <font color=\"red\">-4.5%</font>), ICON (<a href='https://seekingalpha.com/symbol/ICLR' title='Icon PLC'>ICLR</a> <font color=\"red\">-4.5%</font>), IQVIA (<a href='https://seekingalpha.com/symbol/IQV' title='IQVIA Holdings, Inc.'>IQV</a> <font color=\"red\">-3.9%</font>) and PRA Health Sciences (<a href='https://seekingalpha.com/symbol/PRAH' title='PRA Health Sciences'>PRAH</a> <font color=\"red\">-5.3%</font>) are all under pressure in apparent response to Bristol-Myers Squibb's <a href=\"https://seekingalpha.com/news/3420229-bristol-myers-squibb-acquire-celgene-74b\" target=\"_blank\">$74B bid</a> for Celgene.</li><li>Jefferies' Jared Holz says investors typically regard mega mergers as a negative for the CROs, although stocks in the group were down over <font color=\"red\">20%</font> last month.</li><li>Goldman's Robert Jones believes the BMY/CELG merger could be a positive for ICLR since it has a long-term relationship with BMY.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420470\" data-linked=\"Contract research organizations in the red on BMY/CELG tie-up\" data-tweet=\"$CRL $CRL $ICLR - Contract research organizations in the red on BMY/CELG tie-up https://seekingalpha.com/news/3420470-contract-research-organizations-in-red-on-bmy-celg-tie-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3420470-contract-research-organizations-in-red-on-bmy-celg-tie-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420465\" data-ts=\"1546539472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYBX\" target=\"_blank\">SYBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420465-synlogic-up-3-on-key-2019-events\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synlogic up 3% on key 2019 events</a></h4><ul><li>Thinly traded micro cap Synlogic (<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a> <font color=\"green\">+3.1%</font>) is up on below-average volume after <a href=\"https://seekingalpha.com/pr/17369358-synlogic-progresses-clinical-preclinical-pipeline-outlines-2019-catalysts\" target=\"_blank\">announcing </a>key pipeline events for 2019.</li><li>SYNB1020: Topline data from Phase 1b/2a study in patients with cirrhosis and elevated ammonia expected mid-year.</li><li>SYNB1891: IND for Phase 1 study to be filed in H2 for the STING agonist.</li><li>On the capital front, its cash and equivalents should be sufficient to fund operations through 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420465\" data-linked=\"Synlogic up 3% on key 2019 events\" data-tweet=\"$SYBX - Synlogic up 3% on key 2019 events https://seekingalpha.com/news/3420465-synlogic-up-3-on-key-2019-events?source=tweet\" data-url=\"https://seekingalpha.com/news/3420465-synlogic-up-3-on-key-2019-events\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420463\" data-ts=\"1546538586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRTX\" target=\"_blank\">HRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420463-heron-up-3-on-positive-htxminus-011-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heron up 3% on positive HTX-011 data</a></h4><ul><li>Heron Therapeutics (<a href='https://seekingalpha.com/symbol/HRTX' title='Heron Therapeutics, Inc.'>HRTX</a> <font color=\"green\">+2.6%</font>) is up on average volume in response to its <a href=\"https://seekingalpha.com/pr/17369472-90-percent-patients-remain-opioid-free-htxminus-011-given-counter-analgesic-regimen-new-multi\" target=\"_blank\">announcement </a>of positive results from pain management study evaluating the combination of HTX-011 and over-the-counter pain meds (acetaminophen and ibuprofen) for managing postoperative pain.</li><li>90% of patients receiving the combo regimen did not need opioids for postoperative pain through 72 hours after surgery, superior to 51%, 40% and 22% of patients receiving HTX-011, bupivacaine and placebo, respectively.</li><li>81% of patients receiving the combo remained opioid-free through 28 days after surgery.</li><li>The company's U.S. marketing application seeking approval for HTX-011 + meloxicam is currently under FDA review with an action date of April 30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420463\" data-linked=\"Heron up 3% on positive HTX-011 data\" data-tweet=\"$HRTX - Heron up 3% on positive HTX-011 data https://seekingalpha.com/news/3420463-heron-up-3-on-positive-htxminus-011-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3420463-heron-up-3-on-positive-htxminus-011-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420460\" data-ts=\"1546538142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YIN\" target=\"_blank\">YIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420460-yintech-investment-holdings-leads-financial-gainers-warrior-met-coal-and-equity-bancshares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yintech Investment Holdings leads financial gainers; Warrior Met Coal and Equity Bancshares among losers</a></h4><ul><li><b>Gainers:</b> Yintech Investment Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings'>YIN</a>) <font color=\"green\">+7%</font>. Green Brick Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/GRBK' title='Green Brick Partners, Inc'>GRBK</a>) <font color=\"green\">+6%</font>. Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"green\">+6%</font>. Loop Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LOOP' title='Loop Industries, Inc.'>LOOP</a>) <font color=\"green\">+6%</font>. The Simply Good Foods (NASDAQ:<a href='https://seekingalpha.com/symbol/SMPL' title='The Simply Good Foods Company'>SMPL</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a>) <font color=\"red\">-10%</font>. Warrior Met Coal (NYSE:<a href='https://seekingalpha.com/symbol/HCC' title='Warrior Met Coal'>HCC</a>) <font color=\"red\">-7%</font>. Senmiao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AIHS' title='Senmiao Technology'>AIHS</a>) <font color=\"red\">-6%</font>. Equity Bancshares (NASDAQ:<a href='https://seekingalpha.com/symbol/EQBK' title='Equity Bancshares'>EQBK</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420460\" data-linked=\"Yintech Investment Holdings leads financial gainers; Warrior Met Coal and Equity Bancshares among losers\" data-tweet=\"$YIN $YIN $GRBK - Yintech Investment Holdings leads financial gainers; Warrior Met Coal and Equity Bancshares among losers https://seekingalpha.com/news/3420460-yintech-investment-holdings-leads-financial-gainers-warrior-met-coal-and-equity-bancshares?source=tweet\" data-url=\"https://seekingalpha.com/news/3420460-yintech-investment-holdings-leads-financial-gainers-warrior-met-coal-and-equity-bancshares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420457\" data-ts=\"1546537993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNCE\" target=\"_blank\">JNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420457-jounce-advancing-early-stage-study-of-pdminus-1-inhibitor-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jounce advancing early-stage study of PD-1 inhibitor; shares up 2%</a></h4><ul><li>Thinly traded micro cap Jounce Therapeutics (<a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color=\"green\">+2.3%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17369351-jounce-therapeutics-completed-enrollment-first-cohort-phase-1-clinical-trial-pdminus-1\" target=\"_blank\">announcement</a> that it has completed enrollment in the first cohort in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03790488?term=NCT03790488&amp;rank=1\" target=\"_blank\">Phase 1 clinical trial</a> evaluating PD-1 inhibitor JTX-4014 in patients with solid tumors.</li><li>The study's objectives are safety, tolerability and pharmacokinetics and to identify the recommended dose for a Phase 2 trial. The estimated primary completion date is September 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420457\" data-linked=\"Jounce advancing early-stage study of PD-1 inhibitor; shares up 2%\" data-tweet=\"$JNCE - Jounce advancing early-stage study of PD-1 inhibitor; shares up 2% https://seekingalpha.com/news/3420457-jounce-advancing-early-stage-study-of-pdminus-1-inhibitor-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3420457-jounce-advancing-early-stage-study-of-pdminus-1-inhibitor-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420456\" data-ts=\"1546537575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRA\" target=\"_blank\">ATRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420456-atara-bio-in-licenses-car-t-candidate-from-memorial-sloan-kettering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atara Bio in-licenses CAR-T candidate from Memorial Sloan Kettering</a></h4><ul><li>Atara Biotherapeutics (<a href='https://seekingalpha.com/symbol/ATRA' title='Atara Biotherapeutics'>ATRA</a> <font color=\"red\">-9%</font>) has exclusively <a href=\"https://www.google.com/search?q=mesothelin&amp;oq=mesothelin+&amp;aqs=chrome..69i57j69i60j0l4.3951j0j7&amp;sourceid=chrome&amp;ie=UTF-8\" target=\"_blank\">in-licensed</a> a mesothelin-targeted CAR-T therapy from Memorial Sloan Kettering Cancer Center.</li><li>Mesothelin is a protein that is highly expressed in certain cancers, including malignant mesothelioma, pancreatic and ovarian cancer and lung adenocarcinoma.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420456\" data-linked=\"Atara Bio in-licenses CAR-T candidate from Memorial Sloan Kettering\" data-tweet=\"$ATRA - Atara Bio in-licenses CAR-T candidate from Memorial Sloan Kettering https://seekingalpha.com/news/3420456-atara-bio-in-licenses-car-t-candidate-from-memorial-sloan-kettering?source=tweet\" data-url=\"https://seekingalpha.com/news/3420456-atara-bio-in-licenses-car-t-candidate-from-memorial-sloan-kettering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420452\" data-ts=\"1546537303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTAI\" target=\"_blank\">BTAI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420452-healthcare-dominate-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare dominate midday movers</a></h4><ul><li><strong>Gainers: </strong>BioXcel Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BTAI' title='BioXcel Therapeutics'>BTAI</a>) <font color=\"green\">+35%</font>. EDAP TMS S.A. (NASDAQ:<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a>) <font color=\"green\">+27%</font>. Celgene Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) <font color=\"green\">+24%</font>. Lifeway Foods (NASDAQ:<a href='https://seekingalpha.com/symbol/LWAY' title='Lifeway Foods, Inc.'>LWAY</a>) <font color=\"green\">+18%</font>. Cocrystal Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/COCP' title='Cocrystal Pharma, Inc.'>COCP</a>) <font color=\"green\">+16%</font>. MOGU (NYSE:<a href='https://seekingalpha.com/symbol/MOGU' title='MOGU'>MOGU</a>) <font color=\"green\">+17%</font>. Estre Ambiental (NASDAQ:<a href='https://seekingalpha.com/symbol/ESTR' title='Estre Ambiental, Inc.'>ESTR</a>) <font color=\"green\">+16%</font>. IZEA Worldwide (NASDAQ:<a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a>) <font color=\"green\">+15%</font>. Tetraphase Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TTPH' title='Tetraphase Pharmaceuticals'>TTPH</a>) <font color=\"green\">+15%</font>. AzurRx BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/AZRX' title='AzurRX Biopharma'>AZRX</a>) <font color=\"green\">+15%</font>.</li> <li><strong>Losers: </strong>Sesen Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SESN' title='Sesen Bio, Inc.'>SESN</a>) <font color=\"red\">-33%</font>. LightInTheBox Holding (NYSE:<a href='https://seekingalpha.com/symbol/LITB' title='LightInTheBox Holding Co., Ltd.'>LITB</a>) <font color=\"red\">-20%</font>. China Ceramics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a>) <font color=\"red\">-17%</font>. Co-Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/CODX' title='Co-Diagnostics'>CODX</a>) <font color=\"red\">-17%</font>. Prana Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Ltd'>PRAN</a>) <font color=\"red\">-17%</font>. Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"red\">-14%</font>. Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) <font color=\"red\">-14%</font>. Vaxart (NASDAQ:<a href='https://seekingalpha.com/symbol/VXRT' title='Vaxart, Inc.'>VXRT</a>) <font color=\"red\">-16%</font>. Renmin Tianli Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a>) <font color=\"red\">-13%</font>. Fortress Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/FBIO' title='Fortress Biotech, Inc.'>FBIO</a>) <font color=\"red\">-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420452\" data-linked=\"Healthcare dominate midday movers\" data-tweet=\"$BTAI $BTAI $EDAP - Healthcare dominate midday movers https://seekingalpha.com/news/3420452-healthcare-dominate-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420452-healthcare-dominate-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420450\" data-ts=\"1546537064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCRX\" target=\"_blank\">PCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420450-pacira-down-9-on-exparel-sales-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacira down 9% on Exparel sales results</a></h4><ul><li>The market's down day notwithstanding, Pacira Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PCRX' title='Pacira Pharmaceuticals, Inc.'>PCRX</a> <font color=\"red\">-9.1%</font>) is getting rudely treated after <a href=\"https://seekingalpha.com/pr/17369248-pacira-reports-preliminary-2018-net-exparel-sales-331-million\" target=\"_blank\">reporting </a>preliminary Q4 and 2018 sales figures for EXPAREL (bupivacaine liposome injectable suspension).</li><li>Unaudited Q4 and 2018 sales were $94M (+19%) and $331M (+17%), respectively. Full-year guidance was $325M - 330M.</li><li>The company says new reimbursement codes that went into effect on January 1 should boost patient access.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420450\" data-linked=\"Pacira down 9% on Exparel sales results\" data-tweet=\"$PCRX - Pacira down 9% on Exparel sales results https://seekingalpha.com/news/3420450-pacira-down-9-on-exparel-sales-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3420450-pacira-down-9-on-exparel-sales-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420448\" data-ts=\"1546536755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420448-app-store-made-1_22b-over-holidays\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">App Store made $1.22B over holidays</a></h4><ul><li>Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='red'>-8.2%</font>) <a href=\"https://seekingalpha.com/pr/17369886-app-store-caps-record-breaking-2018-blockbuster-holiday-week\" target=\"_blank\">announces</a> that App Store spending topped $1.22B between Christmas Eve and New Year's Eve, a new holiday spending record.</li><li>Customers spent over $322M on New Year's Day alone.</li><li>The announcement follows yesterday's <a href=\"https://seekingalpha.com/news/3420157-apple-cuts-q1-revenue-guidance\" target=\"_blank\">Q1 warning</a> on iPhone weakness in China, which has the Street seeing red. But notable analysts including Morgan Stanley's Katy Huberty have <a href=\"https://seekingalpha.com/news/3409961-buy-apple-supplier-pullback-morgan-stanley\" target=\"_blank\">remained bullish</a> on Apple's Services potential even as weak iPhone data poured in.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420448\" data-linked=\"App Store made $1.22B over holidays\" data-tweet=\"$AAPL - App Store made $1.22B over holidays https://seekingalpha.com/news/3420448-app-store-made-1_22b-over-holidays?source=tweet\" data-url=\"https://seekingalpha.com/news/3420448-app-store-made-1_22b-over-holidays\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420445\" data-ts=\"1546535986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420445-investors-lack-enthusiasm-for-bristol-myers-squibbs-celgene-bid-shares-down-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors lack enthusiasm for Bristol-Myers Squibb&#39;s Celgene bid; shares down 13%</a></h4><ul><li>Investors are clearly signaling their opinion with the premium Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color=\"red\">-12.8%</font>) will pay for Celgene. Shares are down on more than a 5x surge in volume.</li><li>The bid was $50 in cash plus one share of BMY common stock, valued at $102.43 before the open, now worth ~$96 based on recent trade.</li><li>$96 represents a 4.7x multiple of trailing 12-month sales and a 23.9x multiple of trailing 12-month EPS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420445\" data-linked=\"Investors lack enthusiasm for Bristol-Myers Squibb&#39;s Celgene bid; shares down 13%\" data-tweet=\"$BMY - Investors lack enthusiasm for Bristol-Myers Squibb&#39;s Celgene bid; shares down 13% https://seekingalpha.com/news/3420445-investors-lack-enthusiasm-for-bristol-myers-squibbs-celgene-bid-shares-down-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3420445-investors-lack-enthusiasm-for-bristol-myers-squibbs-celgene-bid-shares-down-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420443\" data-ts=\"1546535577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCI\" target=\"_blank\">RCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420443-rogers-communicationsplus-1_6-national-bank-bumps-to-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rogers Communications +1.6% as National Bank bumps to Outperform</a></h4><ul>   <li>Rogers Communications (NYSE:<a href='https://seekingalpha.com/symbol/RCI' title='Rogers Communications Inc.'>RCI</a>) has jumped to a <font color=\"green\">1.6% gain</font> on NYSE, a rare up mover in today's down market, after National Bank Financial upgraded shares to Outperform.</li>    <li>Analyst Adam Shine boosted his price target on the company to C$78 from C$71, implying <font color=\"green\">11.7% upside</font> from current pricing in Toronto.</li>    <li>On NYSE, RCI shares have <font color=\"green\">gained 7.8%</font> over the past six months but are <font color=\"red\">down 3.4%</font> in the past month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420443\" data-linked=\"Rogers Communications +1.6% as National Bank bumps to Outperform\" data-tweet=\"$RCI - Rogers Communications +1.6% as National Bank bumps to Outperform https://seekingalpha.com/news/3420443-rogers-communicationsplus-1_6-national-bank-bumps-to-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3420443-rogers-communicationsplus-1_6-national-bank-bumps-to-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420441\" data-ts=\"1546535275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420441-yields-leg-out-new-lows-after-soft-ism-print\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yields leg out new lows after soft ISM print</a></h4><ul><li><a href=\"https://seekingalpha.com/news/3420356\" target=\"_blank\">The December ISM fell</a> all the way to 54.1 from 59.3 previously. Expectations had been for a rather modest decline to 57.9.</li><li>Leading the drop was a whopping fall in New Orders to 51.1 from 62.1. Production slumped to 54.3 from 60.6, Supplier Deliveries to 57.5 from 62.5, and Employment to 56.2 from 58.4. Prices dropped to 54.9 from 60.7, and Backlogs to 50.0 from 56.4.</li><li>The 10-year Treasury yield is off another four basis points to 2.58%, and the Two-year yield is down five basis points to 2.42%. <a href=\"https://www.cmegroup.com/trading/interest-rates/stir/30-day-federal-fund.html\" target=\"_blank\">Short-term interest rate futures</a> are now pricing in a rate cut in 2019 as more likely than a rate hike - this vs. the Fed \"dots\" which show central planner expectations for 2-3 more rate hikes this year.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a> <font color=\"green\">+1.1%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a> <font color=\"red\">-2.2%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/IEF' title='iShares 7-10 Year Treasury Bond ETF'>IEF</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/PST' title='ProShares UltraShort 7-10 Year Treasury ETF'>PST</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Treasury ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/IEI' title='iShares 3-7 Year Treasury Bond ETF'>IEI</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/VGIT' title='Vanguard Intermediate-Term Treasury ETF'>VGIT</a>, <a href='https://seekingalpha.com/symbol/UST' title='ProShares Ultra 7-10 Year Treasury ETF'>UST</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/DTYS' title='iPath U.S. Treasury 10-Year Bear ETN'>DTYS</a>, <a href='https://seekingalpha.com/symbol/TYO' title='Direxion Daily 10-Year Treasury Bear 3x Shares ETF'>TYO</a>, <a href='https://seekingalpha.com/symbol/SPTL' title='SPDR Portfolio Long Term Treasury ETF'>SPTL</a>, <a href='https://seekingalpha.com/symbol/GSY' title='Invesco Ultra Short Duration ETF'>GSY</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/SCHR' title='Schwab Intermediate-Term U.S. Treasury ETF'>SCHR</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/TBX' title='ProShares Short 7-10 Year Treasury ETF'>TBX</a>, <a href='https://seekingalpha.com/symbol/TYD' title='Direxion Daily 10-Year Treasury Bull 3x Shares ETF'>TYD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3420441\" data-linked=\"Yields leg out new lows after soft ISM print\" data-tweet=\"$TLT $TBT $TMV - Yields leg out new lows after soft ISM print https://seekingalpha.com/news/3420441-yields-leg-out-new-lows-after-soft-ism-print?source=tweet\" data-url=\"https://seekingalpha.com/news/3420441-yields-leg-out-new-lows-after-soft-ism-print\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420437\" data-ts=\"1546535141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420437-tech-lunch-apple-suppliers-drag-street\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech lunch: Apple, suppliers drag the Street</a></h4><ul><li>Apple's <a href=\"https://seekingalpha.com/news/3420157-apple-cuts-q1-revenue-guidance\" target=\"_blank\">Q1 guidance cut</a> is weighing on the Street today with suppliers along for the ride. Mellanox is also plunging on <a href=\"https://seekingalpha.com/news/3420374-piper-new-mellanox-cfo-means-acquisition\" target=\"_blank\">concerns</a> its new CFO appointment means the company won't pursue a sale.</li><li>The tech sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) is <font color=\"red\">down 3.4%</font> with the tech-heavy Nasdaq 100 <font color=\"red\">down 1.9%</font>, the S&amp;P 500 IT Index <font color=\"red\">-3.5%</font>, and the Philadelphia Semiconductor Index <font color=\"red\">falling 4.3%</font>.</li><li>Related semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3420437\" data-linked=\"Tech lunch: Apple, suppliers drag the Street\" data-tweet=\"$XLK $SOXL $SOXX - Tech lunch: Apple, suppliers drag the Street https://seekingalpha.com/news/3420437-tech-lunch-apple-suppliers-drag-street?source=tweet\" data-url=\"https://seekingalpha.com/news/3420437-tech-lunch-apple-suppliers-drag-street\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420432\" data-ts=\"1546534963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRBP\" target=\"_blank\">CRBP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420432-corbus-pharma-up-6-on-kaken-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corbus Pharma up 6% on Kaken collaboration</a></h4><ul><li>Corbus Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a> <font color=\"green\">+5.6%</font>) is up on 33% higher volume in response to its <a href=\"https://seekingalpha.com/pr/17369751-corbus-pharmaceuticals-announces-strategic-collaboration-kaken-pharmaceutical-co-ltd-develop\" target=\"_blank\">collaboration </a>with Kaken Pharmaceutical Co., Ltd. aimed at developing and commercializing lenabasum in Japan for systemic sclerosis and dermatomyositis.</li><li>Under the terms of the partnership, Corbus will receive $27M upfront, up to $173M in milestones and double-digit royalties on net sales. Kaken will have exclusive in-country rights to lenabasum for the two indications.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420432\" data-linked=\"Corbus Pharma up 6% on Kaken collaboration\" data-tweet=\"$CRBP - Corbus Pharma up 6% on Kaken collaboration https://seekingalpha.com/news/3420432-corbus-pharma-up-6-on-kaken-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3420432-corbus-pharma-up-6-on-kaken-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420435\" data-ts=\"1546534934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LWAY\" target=\"_blank\">LWAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420435-new-age-beverages-and-china-xd-plastics-among-consumer-gainers-apple-and-fabrinet-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages and China XD Plastics among consumer gainers; Apple and Fabrinet among losers</a></h4><ul><li><b>Gainers: </b>Lifeway Foods (NASDAQ:<a href='https://seekingalpha.com/symbol/LWAY' title='Lifeway Foods, Inc.'>LWAY</a>) <font color=\"green\">+14%</font>. Eastside Distilling (NASDAQ:<a href='https://seekingalpha.com/symbol/EAST' title='Eastside Distilling, Inc.'>EAST</a>) <font color=\"green\">+8%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp. Ltd.'>SOLO</a>) <font color=\"green\">+7%</font>. New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+6%</font>. China XD Plastics Company (NASDAQ:<a href='https://seekingalpha.com/symbol/CXDC' title='China XD Plastics Company Limited'>CXDC</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Renmin Tianli Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a>) <font color=\"red\">-13%</font>. Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) <font color=\"red\">-8%</font>. Liberty TripAdvisor Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LTRPA' title='Liberty TripAdvisor Holdings A'>LTRPA</a>) <font color=\"red\">-7%</font>. Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) <font color=\"red\">-5%</font>. Arcimoto (NASDAQ:<a href='https://seekingalpha.com/symbol/FUV' title='Arcimoto, Inc.'>FUV</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420435\" data-linked=\"New Age Beverages and China XD Plastics among consumer gainers; Apple and Fabrinet among losers\" data-tweet=\"$LWAY $LWAY $EAST - New Age Beverages and China XD Plastics among consumer gainers; Apple and Fabrinet among losers https://seekingalpha.com/news/3420435-new-age-beverages-and-china-xd-plastics-among-consumer-gainers-apple-and-fabrinet-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3420435-new-age-beverages-and-china-xd-plastics-among-consumer-gainers-apple-and-fabrinet-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420434\" data-ts=\"1546534900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPACE\" target=\"_blank\">SPACE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420434-iridium-set-to-wrap-up-next-gen-satellite-deployment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iridium set to wrap up next-gen satellite deployment</a></h4><ul>   <li>Iridium (<a href=\"http://seekingalpha.com/symbol/IRDM\" target=\"_blank\">IRDM</a> <font color=\"red\">-1.7%</font>) is set to wrap up its NEXT satellite deployment, with the last 10 satellites mated, fueled and ready to launch on Tuesday, the company's CEO says.</li>    <li>Matt Desch says the company will deploy the last of the next-generation satellites Jan. 8 with help from SpaceX (<a href='https://seekingalpha.com/symbol/SPACE' title='SpaceX'>SPACE</a>). A <a href=\"https://seekingalpha.com/news/3364291-iridium-sets-july-20-seventh-next-launch\" target=\"_blank\">launch last summer</a> brought the total number of NEXT satellites to 65; the new launch will bring full deployment of 75.</li>    <li>With the deployment completed, 2019 will mark a decline in capital spending for Iridium, Desch says.</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420434\" data-linked=\"Iridium set to wrap up next-gen satellite deployment\" data-tweet=\"$SPACE $SPACE $IRDM - Iridium set to wrap up next-gen satellite deployment https://seekingalpha.com/news/3420434-iridium-set-to-wrap-up-next-gen-satellite-deployment?source=tweet\" data-url=\"https://seekingalpha.com/news/3420434-iridium-set-to-wrap-up-next-gen-satellite-deployment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420427\" data-ts=\"1546534501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POAHY\" target=\"_blank\">POAHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420427-porsche-u-s-retail-salesplus-4_4-in-december\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Porsche U.S. retail sales +4.4% in December</a></h4><ul><li>Porsche (<a href='https://seekingalpha.com/symbol/POAHY' title='Porsche Automobile Holding SE ADR'>OTCPK:POAHY</a>) unit sales rose <a href=\"https://seekingalpha.com/pr/17369842-porsche-sets-u-s-retail-sales-record-2018\" target=\"_blank\">4.4%</a> to 4,086 units in December.</li><li>911 sales up 2.1% to 789 units.</li><li>718 sales fell 21.3% to 237 units</li><li>Cayenne sales increased 47.1% to 1,383 units.</li><li>Panamera sales down 27% to 332 units.</li><li>Macan sales grew 6.9% to 1,345 units.</li><li>YTD Porsche U.S. sales +3.2% to 57,202 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420427\" data-linked=\"Porsche U.S. retail sales +4.4% in December\" data-tweet=\"$POAHY $POAHF - Porsche U.S. retail sales +4.4% in December https://seekingalpha.com/news/3420427-porsche-u-s-retail-salesplus-4_4-in-december?source=tweet\" data-url=\"https://seekingalpha.com/news/3420427-porsche-u-s-retail-salesplus-4_4-in-december\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420426\" data-ts=\"1546534457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBLN\" target=\"_blank\">OBLN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420426-obalon-down-14-after-commercial-plan-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Obalon down 14% after commercial plan update</a></h4><ul><li>Thinly traded nano cap Obalon Therapeutics (<a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a> <font color=\"red\">-13.9%</font>) slumps on average volume following its <a href=\"https://seekingalpha.com/pr/17368463-obalon-host-call-provide-update-commercial-strategy-post-fda-approval-obalon-navigation\" target=\"_blank\">conference call</a> this morning to update investors on its commercial plan for its Navigation System that supports the placement of its intragastric balloon for the treatment of obesity without the need for an x-ray.</li><li>Investors appear disappointed that the Navigation System is not compatible with the current balloon kit that relies on x-ray guidance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420426\" data-linked=\"Obalon down 14% after commercial plan update\" data-tweet=\"$OBLN - Obalon down 14% after commercial plan update https://seekingalpha.com/news/3420426-obalon-down-14-after-commercial-plan-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3420426-obalon-down-14-after-commercial-plan-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420419\" data-ts=\"1546533589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CATB\" target=\"_blank\">CATB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420419-catabasis-pharma-up-6-on-clinical-advancement-of-dmd-candidate-edasalonexent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catabasis Pharma up 6% on clinical advancement of DMD candidate edasalonexent</a></h4><ul><li>Catabasis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color=\"green\">+6.1%</font>) is up on below-average volume in response to its <a href=\"https://seekingalpha.com/pr/17369426-catabasis-pharmaceuticals-phase-3-polarisdmd-clinical-trial-edasalonexent-duchenne-muscular\" target=\"_blank\">update </a>on its Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03703882?lead=catabasis&amp;phase=2&amp;rank=1\" target=\"_blank\">PolarisDMD</a>, evaluating edasalonexent (CAT-1004) in boys with Duchenne muscular dystrophy &#40;DMD&#41;.</li><li>Nine U.S. trial sites are now open with at least 10 more expected to open shortly. Sites in Canada will come on line this month followed by sites in Europe, Australia and Israel later this quarter. A total of 40 sites will eventually participate.</li><li>The primary endpoint is the change from baseline in North Star Ambulatory Assessment &#40;NSAA&#41; at week 52. Topline data should be available in Q2 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420419\" data-linked=\"Catabasis Pharma up 6% on clinical advancement of DMD candidate edasalonexent\" data-tweet=\"$CATB - Catabasis Pharma up 6% on clinical advancement of DMD candidate edasalonexent https://seekingalpha.com/news/3420419-catabasis-pharma-up-6-on-clinical-advancement-of-dmd-candidate-edasalonexent?source=tweet\" data-url=\"https://seekingalpha.com/news/3420419-catabasis-pharma-up-6-on-clinical-advancement-of-dmd-candidate-edasalonexent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420418\" data-ts=\"1546533009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFTBY\" target=\"_blank\">SFTBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420418-bloomberg-softbank-hires-goldman-veteran-for-new-investment-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: SoftBank hires Goldman veteran for new investment unit</a></h4><ul>   <li>SoftBank (<a href=\"http://seekingalpha.com/symbol/SFTBY\" target=\"_blank\">SFTBY</a> <font color=\"red\">-1.2%</font>) has hired a Goldman Sachs (<a href=\"http://seekingalpha.com/symbol/GS\" target=\"_blank\">GS</a> <font color=\"red\">-1.7%</font>) veteran to <a href=\"https://www.bloomberg.com/news/articles/2019-01-03/softbank-is-said-to-hire-goldman-veteran-kimoto-for-investments\" target=\"_blank\">head up a new investment unit</a>, Bloomberg reports.</li>    <li>The company has hired Hiroki Kimoto, an 18-year Goldman employee, in the latest move in SoftBank's evolution from telecom to tech investment giant.</li>    <li>Kimoto most recently was managing director of Asian Special Situations in Goldman's Securities Division, where he helped the firm invest in Japanese golf courses, hot springs and distressed assets. He joins SoftBank on Friday, according to the report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420418\" data-linked=\"Bloomberg: SoftBank hires Goldman veteran for new investment unit\" data-tweet=\"$SFTBY $SFTBY $GS - Bloomberg: SoftBank hires Goldman veteran for new investment unit https://seekingalpha.com/news/3420418-bloomberg-softbank-hires-goldman-veteran-for-new-investment-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3420418-bloomberg-softbank-hires-goldman-veteran-for-new-investment-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420414\" data-ts=\"1546532719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCRB\" target=\"_blank\">MCRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420414-seres-up-7-on-launch-of-mid-stage-study-of-serminus-287-in-ulcerative-colitis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seres up 7% on launch of mid-stage study of SER-287 in ulcerative colitis</a></h4><ul><li>Thinly traded micro cap Seres Therapeutics (<a href='https://seekingalpha.com/symbol/MCRB' title='Seres Therapeutics'>MCRB</a> <font color=\"green\">+7.2%</font>) is up on below-average volume on the heels of the <a href=\"https://seekingalpha.com/pr/17369169-seres-therapeutics-announces-initiation-serminus-287-phase-2b-eco-reset-clinical-study\" target=\"_blank\">launch </a>of a pivotal Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03759041\" target=\"_blank\">ECO-RESET</a>, evaluating microbiome therapeutic candidate SER-287 in patients with active mild-to-moderate ulcerative colitis.</li><li>The start of the study triggered $40M in milestone payments from Nestlé Health Science.</li><li>The primary endpoint of the 201-subject trial is the clinical remission rate after 10 weeks of dosing. The estimated primary completion date is July 2020.</li><li>The company says the results, together with data from a second pivotal study, could support a U.S. marketing application.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420414\" data-linked=\"Seres up 7% on launch of mid-stage study of SER-287 in ulcerative colitis\" data-tweet=\"$MCRB - Seres up 7% on launch of mid-stage study of SER-287 in ulcerative colitis https://seekingalpha.com/news/3420414-seres-up-7-on-launch-of-mid-stage-study-of-serminus-287-in-ulcerative-colitis?source=tweet\" data-url=\"https://seekingalpha.com/news/3420414-seres-up-7-on-launch-of-mid-stage-study-of-serminus-287-in-ulcerative-colitis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420412\" data-ts=\"1546532586\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSANF\" target=\"_blank\">NSANF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420412-nissan-u-s-sales-up-7_6-in-december\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nissan U.S. sales up 7.6% in December</a></h4><ul><li>Nissan (<a href='https://seekingalpha.com/symbol/NSANY' title='Nissan Motor Co., Ltd. ADR'>OTCPK:NSANY</a>) unit sales <a href=\"https://seekingalpha.com/pr/17369798-nissan-group-reports-december-2018-2018-calendar-year-u-s-sales\" sasource=\"qp_sum_news_21\" target=\"_blank\">+7.6%</a> to 148,720 units vs. -6.1% forecast by Edmunds.</li><li>Nissan truck sales grew 14% Y/Y to 95,174 units.</li><li>Nissan car sales down 2.1% to 53,546 units.</li><li>Sales growth by brand: Nissan +7.2% to 130,655 units; Infiniti +10.3% to 18,065 units.</li><li>Rogue sales up 6% to 42,523 units during the month.</li><li>Sentra +4.4% to 17,567 units.</li><li>YTD Nissan sales slipped 6.2% to 1,493,877 units.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420412\" data-linked=\"Nissan U.S. sales up 7.6% in December\" data-tweet=\"$NSANF $NSANY - Nissan U.S. sales up 7.6% in December https://seekingalpha.com/news/3420412-nissan-u-s-sales-up-7_6-in-december?source=tweet\" data-url=\"https://seekingalpha.com/news/3420412-nissan-u-s-sales-up-7_6-in-december\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420409\" data-ts=\"1546532256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDR\" target=\"_blank\">CLDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420409-cloudera-hortonworks-merger-closes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cloudera-Hortonworks merger closes</a></h4><ul><li>The Cloudera (<a href='https://seekingalpha.com/symbol/CLDR' title='Cloudera, Inc.'>CLDR</a> <font color='red'>-8.8%</font>) and Hortonwork (NASDAQ:<a href='https://seekingalpha.com/symbol/HDP' title='Hortonworks'>HDP</a>) merger <a href=\"https://seekingalpha.com/pr/17369658-cloudera-hortonworks-complete-planned-merger\" target=\"_blank\">closes </a>today with CLDR remaining as the publicly-traded ticker.</li><li>Hortonworks shareholders <a href=\"https://seekingalpha.com/news/3394930-cloudera-soars-hortonworks-merger\" target=\"_blank\">received</a> 1.305 Cloudera shares for each HDP share in the all-stock merger. Cloudera holders will own about 60% of the equity of the combined company.</li><li>Cloudera execs will host a conference call on January 10 at 1:00 PM ET to discuss the new company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420409\" data-linked=\"Cloudera-Hortonworks merger closes\" data-tweet=\"$CLDR $CLDR $HDP - Cloudera-Hortonworks merger closes https://seekingalpha.com/news/3420409-cloudera-hortonworks-merger-closes?source=tweet\" data-url=\"https://seekingalpha.com/news/3420409-cloudera-hortonworks-merger-closes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420408\" data-ts=\"1546532007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420408-double-whammy-for-berkshire-hathaway\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">A double-whammy for Berkshire Hathaway</a></h4><ul><li>Apple's (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='red'>-8.9%</font>) decline after cutting its Q1 revenue guidance means at least ~$3.8B paper loss for Berkshire Hathaway's (<a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway B'>BRK.B</a> <font color='red'>-4.3%</font>)(<a href='https://seekingalpha.com/symbol/BRK.A' title='Berkshire Hathaway A'>BRK.A</a> <font color='red'>-4.3%</font>) 252M-share stake in the maker of iPhones.</li><li>Berkshire's stock is taking an even bigger hit. Markets are down broadly as Apple's lower expectations stem from weaker demand from China.</li><li>With B shares losing $8.64 in late morning trading multiplied by 2.46B shares outstanding, Berkshire has lost $21.4B in market cap just this morning.</li><li>The Oracle of Omaha, though, is famous for focusing on long-term returns and ignoring the day-to-day gyrations of the stock market.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420330-berkshire-hathaway-goes-30-year-fixed-1b-debt\" target=\"_blank\">Berkshire Hathaway goes 30-year fixed on $1B in debt</a> (Jan. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3420408\" data-linked=\"A double-whammy for Berkshire Hathaway\" data-tweet=\"$AAPL $AAPL $BRK.B - A double-whammy for Berkshire Hathaway https://seekingalpha.com/news/3420408-double-whammy-for-berkshire-hathaway?source=tweet\" data-url=\"https://seekingalpha.com/news/3420408-double-whammy-for-berkshire-hathaway\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>185&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420407\" data-ts=\"1546531958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYPT\" target=\"_blank\">EYPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420407-eyepoint-pharma-readies-two-product-launches-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EyePoint Pharma readies two product launches; shares up 2%</a></h4><ul><li>EyePoint Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EYPT' title='EyePoint Pharmaceuticals, Inc.'>EYPT</a> <font color=\"green\">+2.1%</font>) plans to <a href=\"https://seekingalpha.com/pr/17369199-eyepoint-pharmaceuticals-provides-2019-commercial-update\" target=\"_blank\">launch </a>two products this quarter, DEXYCU (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation in the eye, and YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg for the long-term treatment of non-infectious posterior segment uveitis.</li><li>CEO Nancy Lurker says manufacturing has been scaled up and commercial infrastructure established to support the launches.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420407\" data-linked=\"EyePoint Pharma readies two product launches; shares up 2%\" data-tweet=\"$EYPT - EyePoint Pharma readies two product launches; shares up 2% https://seekingalpha.com/news/3420407-eyepoint-pharma-readies-two-product-launches-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3420407-eyepoint-pharma-readies-two-product-launches-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420397\" data-ts=\"1546531393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420397-amicus-launches-phase-1-2-study-of-gene-therapy-for-batten-disease-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus launches Phase 1/2 study of gene therapy for Batten disease; shares up 4%</a></h4><ul><li>Amicus Therapeutics (<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a> <font color=\"green\">+4.3%</font>) initiates a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03770572?term=NCT03770572&amp;rank=1\" target=\"_blank\">Phase 1/2 clinical trial</a> evaluating gene therapy candidate AAV9-CLN3 in children with <a href=\"https://ghr.nlm.nih.gov/condition/cln3-disease\" target=\"_blank\">CLN3 Batten disease</a>, an inherited nervous system disorder characterized by intellectual disability, vision impairment and seizures.</li><li>The study will enroll seven children ages 3 - 10. The first patient has been dosed and showed no serious adverse events during the one-month observation period.</li><li>The estimated completion date is December 2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420397\" data-linked=\"Amicus launches Phase 1/2 study of gene therapy for Batten disease; shares up 4%\" data-tweet=\"$FOLD - Amicus launches Phase 1/2 study of gene therapy for Batten disease; shares up 4% https://seekingalpha.com/news/3420397-amicus-launches-phase-1-2-study-of-gene-therapy-for-batten-disease-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3420397-amicus-launches-phase-1-2-study-of-gene-therapy-for-batten-disease-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420405\" data-ts=\"1546531384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTAI\" target=\"_blank\">BTAI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420405-celgene-and-alliqua-biomedical-among-healthcare-gainers-bristol-myers-squibb-and-prana\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celgene and Alliqua BioMedical among healthcare gainers; Bristol-Myers Squibb and Prana Biotechnology among losers</a></h4><ul><li><b>Gainers: </b>BioXcel Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BTAI' title='BioXcel Therapeutics'>BTAI</a>) <font color=\"green\">+27%</font>. Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) <font color=\"green\">+25%</font>. Alliqua BioMedical (NASDAQ:<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a>) <font color=\"green\">+20%</font>. ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a>) <font color=\"green\">+12%</font>. AVROBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/AVRO' title='AVROBIO'>AVRO</a>) <font color=\"green\">+11%</font>.</li><li><b>Losers: </b>Sesen Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SESN' title='Sesen Bio, Inc.'>SESN</a>) <font color=\"red\">-31%</font>. Obalon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OBLN' title='Obalon Therapeutics'>OBLN</a>) <font color=\"red\">-22%</font>. Prana Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Ltd'>PRAN</a>) <font color=\"red\">-16%</font>. Fortress Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/FBIO' title='Fortress Biotech, Inc.'>FBIO</a>) <font color=\"red\">-13%</font>. Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420405\" data-linked=\"Celgene and Alliqua BioMedical among healthcare gainers; Bristol-Myers Squibb and Prana Biotechnology among losers\" data-tweet=\"$BTAI $BTAI $CELG - Celgene and Alliqua BioMedical among healthcare gainers; Bristol-Myers Squibb and Prana Biotechnology among losers https://seekingalpha.com/news/3420405-celgene-and-alliqua-biomedical-among-healthcare-gainers-bristol-myers-squibb-and-prana?source=tweet\" data-url=\"https://seekingalpha.com/news/3420405-celgene-and-alliqua-biomedical-among-healthcare-gainers-bristol-myers-squibb-and-prana\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420398\" data-ts=\"1546531166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YETI\" target=\"_blank\">YETI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420398-yeti-cools-off\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yeti cools off</a></h4><ul> <li>Yeti Holdings (NYSE:<a href='https://seekingalpha.com/symbol/YETI' title='Yeti Holdings'>YETI</a>) is <font color=\"red\">down 7.2%</font> today after a post-Christmas rally had pushed shares back over $16.</li> <li>The consumer products stock sits well-below the IPO pricing level of $18.</li> <li>During an investor presentation last month, Yeti outlined its \"highly attractive\" shift in demographics that included a higher percentage of non-hunters (62% from 31%), under 45-year old customers (70% from 64%) and women (34% from 9%).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420398\" data-linked=\"Yeti cools off\" data-tweet=\"$YETI - Yeti cools off https://seekingalpha.com/news/3420398-yeti-cools-off?source=tweet\" data-url=\"https://seekingalpha.com/news/3420398-yeti-cools-off\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420395\" data-ts=\"1546530913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNK\" target=\"_blank\">GNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420395-genco-shippingplus-3-after-maxim-starts-buy-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genco Shipping +3% after Maxim starts with Buy rating</a></h4><ul><li>Genco Shipping (<a href='https://seekingalpha.com/symbol/GNK' title='Genco Shipping & Trading Ltd.'>GNK</a> <font color='green'>+3.3%</font>) gains after Maxim Group initiates coverage with a <a href=\"https://www.streetinsider.com/Hot+New+Coverage/Maxim+Group+Starts+Genco+Shipping+%28GNK%29+at+Buy/14968140.html\" target=\"_blank\">Buy rating</a> and $22 price target, as the company's methodical approach to IMO 2020 should enable it to realize higher fuel savings and earn above market-rates for its Capesize fleet ahead of its peers.</li><li>With the dry bulk sector climbing towards mid-cycle rates, Maxim says it looks for EPS expansion of 376% in 2019 and 87% in 2020 as the IMO 2020 regulations allows for the global fleet to slow-steam, essentially shrinking the fleet.</li><li>The firm also notes that successful refinancing of facilities has pushed out maturities to Q2 2023 from Q3 2020, which affords capital for fleet renewal and expansion.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420395\" data-linked=\"Genco Shipping +3% after Maxim starts with Buy rating\" data-tweet=\"$GNK - Genco Shipping +3% after Maxim starts with Buy rating https://seekingalpha.com/news/3420395-genco-shippingplus-3-after-maxim-starts-buy-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3420395-genco-shippingplus-3-after-maxim-starts-buy-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420394\" data-ts=\"1546530808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENTA\" target=\"_blank\">ENTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420394-enanta-announces-key-pipeline-events-for-2019\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enanta announces key pipeline events for 2019</a></h4><ul><li>Ahead of its presentation at JPM19 next week, Enanta Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ENTA' title='Enanta Pharmaceuticals, Inc.'>ENTA</a> <font color=\"red\">-4.7%</font>) <a href=\"https://seekingalpha.com/pr/17369300-enanta-pharmaceuticals-provide-updates-research-development-programs-business-outlook-2019\" target=\"_blank\">releases </a>its key pipeline milestones for the year.</li><li>EDP-938: Topline data from a Phase 2a RSV study expected mid-year.</li><li>EDP-514: Preclinical HBV data will be presented on January 7 at JPM19 that showed a 4-log (10,000x) reduction in viral load. A Phase 1 study should launch in H2.</li><li>EDP-305: Enrollment in Phase 2a NASH study should be completed this quarter. Preliminary data expected in Q3. A follow-on FXR candidate should be identified this year.</li><li>#JPM19</li></ul><div class=\"tiny-share-widget\" data-id=\"3420394\" data-linked=\"Enanta announces key pipeline events for 2019\" data-tweet=\"$ENTA - Enanta announces key pipeline events for 2019 https://seekingalpha.com/news/3420394-enanta-announces-key-pipeline-events-for-2019?source=tweet\" data-url=\"https://seekingalpha.com/news/3420394-enanta-announces-key-pipeline-events-for-2019\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420392\" data-ts=\"1546530570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420392-wedbush-bullish-despite-apples-darkest-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush bullish despite &quot;Apple&#39;s darkest day&quot;</a></h4><ul><li>Wedbush analyst Daniel Ives lowers his Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='red'>-9.8%</font>) target from $275 to $200 and calls the <a href=\"https://seekingalpha.com/news/3420157-apple-cuts-q1-revenue-guidance\" target=\"_blank\">Q1 warning</a> \"Apple's darkest day.\"</li><li>Ives: \"Apple\u2019s decisions over the coming months around pricing, future hardware redesigns, timing of 5G smartphones, and driving its core services business will have implications for years to come as Cupertino now faces the biggest fear among bulls which is an installed base (we estimate roughly 750 million active iPhones worldwide) that could stall out and not grow over the coming years and in a nightmare scenario decline.\"</li><li>The analyst maintains an Outperform rating and says he remains bullish on the Apple story despite yesterday's \"black eye.\"</li><li>Source: Research note.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420392\" data-linked=\"Wedbush bullish despite &quot;Apple&#39;s darkest day&quot;\" data-tweet=\"$AAPL - Wedbush bullish despite &quot;Apple&#39;s darkest day&quot; https://seekingalpha.com/news/3420392-wedbush-bullish-despite-apples-darkest-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3420392-wedbush-bullish-despite-apples-darkest-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420391\" data-ts=\"1546530107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420391-oncology-players-in-red-on-celgene-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oncology players in the red on Celgene deal</a></h4><ul><li>A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color=\"red\">-9%</font>)(<a href='https://seekingalpha.com/symbol/CRVS' title='Corvus Pharmaceuticals'>CRVS</a> <font color=\"red\">-9.4%</font>)(<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color=\"red\">-6.8%</font>)(<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color=\"red\">-4.8%</font>)(<a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color=\"red\">-4.8%</font>)(<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color=\"red\">-2.2%</font>)(<a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color=\"red\">-4.1%</font>)(<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color=\"red\">-3.4%</font>)(<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color=\"red\">-3.8%</font>)(<a href='https://seekingalpha.com/symbol/FPRX' title='Five Prime Therapeutics, Inc.'>FPRX</a> <font color=\"red\">-3.6%</font>)(<a href='https://seekingalpha.com/symbol/LABU' title='Direxion Daily S&P Biotech Bull 3x Shares ETF'>LABU</a> <font color=\"red\">-5.8%</font>)(<a href='https://seekingalpha.com/symbol/BPMC' title='Blueprint Medicines'>BPMC</a> <font color=\"red\">-4%</font>)(<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color=\"red\">-4.5%</font>)(<a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a> <font color=\"red\">-2%</font>)(<a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color=\"red\">-1.9%</font>)(<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a> <font color=\"red\">-1.8%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420229-bristol-myers-squibb-acquire-celgene-74b\" target=\"_blank\">Bristol-Myers Squibb to acquire Celgene for $74B</a> (Jan. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3420391\" data-linked=\"Oncology players in the red on Celgene deal\" data-tweet=\"$NLNK $NLNK $CRVS - Oncology players in the red on Celgene deal https://seekingalpha.com/news/3420391-oncology-players-in-red-on-celgene-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3420391-oncology-players-in-red-on-celgene-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420385\" data-ts=\"1546529605\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGNE\" target=\"_blank\">BGNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420385-beigene-down-10-on-celgene-takeout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BeiGene down 10% on Celgene takeout</a></h4><ul><li>BeiGene (<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a> <font color=\"red\">-10.4%</font>) is down on almost double normal in apparent reaction to Bristol-Myers Squibb's $74B bid for Celgene which should satisfy its appetite for additional large transactions, at least in the near term.</li><li>Acceleron Pharma (<a href='https://seekingalpha.com/symbol/XLRN' title='Acceleron Pharma Inc.'>XLRN</a> <font color=\"red\">-6.5%</font>) and Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color=\"red\">-8.5%</font>), both potential acquisition targets, are down as well.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420229-bristol-myers-squibb-acquire-celgene-74b\" target=\"_blank\">Bristol-Myers Squibb to acquire Celgene for $74B</a> (Jan. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3420385\" data-linked=\"BeiGene down 10% on Celgene takeout\" data-tweet=\"$BGNE $BGNE $XLRN - BeiGene down 10% on Celgene takeout https://seekingalpha.com/news/3420385-beigene-down-10-on-celgene-takeout?source=tweet\" data-url=\"https://seekingalpha.com/news/3420385-beigene-down-10-on-celgene-takeout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420377\" data-ts=\"1546528879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCPH\" target=\"_blank\">DCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420377-deciphera-launches-new-study-of-rebastinib-in-solid-tumors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deciphera launches new study of rebastinib in solid tumors</a></h4><ul><li>Deciphera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a> <font color=\"red\">-5.2%</font>) <a href=\"https://clinicaltrials.gov/ct2/show/NCT03717415?term=NCT03717415&amp;rank=1\" target=\"_blank\">initiates </a>a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03717415?term=NCT03717415&amp;rank=1\" target=\"_blank\">Phase 1b/2 clinical trial</a> evaluating rebastinib, a small molecule switch control TIE2 kinase inhibitor, in patients with advanced/metastatic solid tumors (in combination with the chemo agent carboplatin).</li><li>Part one is the dose escalation phase that will determine the recommended dose for the second phase.</li><li>The co-primary endpoints of the 117-subject study are safety (adverse events) and objective response rate at month 24. The estimated completion date is November 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420377\" data-linked=\"Deciphera launches new study of rebastinib in solid tumors\" data-tweet=\"$DCPH - Deciphera launches new study of rebastinib in solid tumors https://seekingalpha.com/news/3420377-deciphera-launches-new-study-of-rebastinib-in-solid-tumors?source=tweet\" data-url=\"https://seekingalpha.com/news/3420377-deciphera-launches-new-study-of-rebastinib-in-solid-tumors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420378\" data-ts=\"1546528864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPOT\" target=\"_blank\">SPOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420378-ft-on-spotify-india-licensing-talks-stuck\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FT on Spotify: India licensing talks stuck</a></h4><ul>   <li>Part of a big <i>Financial Times</i> <a href=\"https://www.ft.com/content/2b1b317a-f87b-11e8-8b7c-6fa24bd5409c\" target=\"_blank\">report</a> on Spotify's (<a href=\"http://seekingalpha.com/symbol/SPOT\" target=\"_blank\">SPOT</a> <font color=\"red\">-3.2%</font>) efforts to replicate Latin American success around the world is reporting that the company's licensing talks in India are at a dead end.</li>    <li>Investors are hoping that Spotify can repeat rapid growth in the U.S., Europe and now Latin America (with little investment) in the \"rest of the world.\" At home, Apple recently bumped Spotify as the most popular paid music streaming service.</li>    <li>Spotify made a November debut in the Middle East and last year also entered South Africa, Israel, Vietnam and Romania.</li>    <li>But in India, large labels still haven't given Spotify a licensing green light, the FT says. Seeing that Spotify now needs growth as a publicly traded company, the labels are pushing back on Spotify requests to offer free trials for several months.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3420378\" data-linked=\"FT on Spotify: India licensing talks stuck\" data-tweet=\"$SPOT - FT on Spotify: India licensing talks stuck https://seekingalpha.com/news/3420378-ft-on-spotify-india-licensing-talks-stuck?source=tweet\" data-url=\"https://seekingalpha.com/news/3420378-ft-on-spotify-india-licensing-talks-stuck\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420374\" data-ts=\"1546528705\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420374-piper-new-mellanox-cfo-means-no-acquisition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper: New Mellanox CFO means no acquisition</a></h4><ul><li>Piper Jaffray thinks Mellanox Tech's (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) <a href=\"https://seekingalpha.com/news/3420293-mellanox-tech-appoints-cfo\" target=\"_blank\">new CFO</a> indicates the company is no longer looking to sell itself but notes the CFO's contract includes some \"unusual language\" that doesn't entirely rule out the possibility.</li><li>The firm senses Mellanox was in deep talks with potential buyers but no deal was reached.</li><li>Rating reiterated at Overweight with a $110 target.</li><li>Source: Bloomberg First Word.</li><li>In November, CNBC <a href=\"https://seekingalpha.com/news/3406681-mellanox-plus-6_7-percent-report-xilinx-hires-barclays-examine-buyout\" target=\"_blank\">reported</a> that Xilinx (NASDAQ:<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a>) was interested in making a bid for Mellanox. Last month, Microsoft was<a href=\"https://seekingalpha.com/news/3418217-mellanox-plus-4-percent-report-microsoft-acquisition-interest\" target=\"_blank\"> rumored</a> to show interest.</li><li>MLNX shares are <font color=\"red\">down 11.6%</font>. Xilinx shares are <font color=\"red\">down 4.1%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420374\" data-linked=\"Piper: New Mellanox CFO means no acquisition\" data-tweet=\"$MLNX $MLNX $XLNX - Piper: New Mellanox CFO means no acquisition https://seekingalpha.com/news/3420374-piper-new-mellanox-cfo-means-no-acquisition?source=tweet\" data-url=\"https://seekingalpha.com/news/3420374-piper-new-mellanox-cfo-means-no-acquisition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420366\" data-ts=\"1546528278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VCYT\" target=\"_blank\">VCYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420366-veracyte-teams-up-j-and-j-in-lung-cancer-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veracyte teams up with J&amp;J in lung cancer; shares up 2%</a></h4><ul><li>Veracyte (<a href='https://seekingalpha.com/symbol/VCYT' title='Veracyte, Inc.'>VCYT</a> <font color=\"green\">+2.1%</font>) inks a long-term strategic <a href=\"https://seekingalpha.com/pr/17369196-veracyte-announces-strategic-collaboration-johnson-and-johnson-innovation-battle-lung-cancer\" target=\"_blank\">collaboration</a> agreement with Johnson &amp; Johnson's (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color=\"red\">-1.5%</font>) Innovation unit and the Lung Cancer Initiative to develop and commercialize diagnostic tests to detect lung cancer at its earliest stages when it is most treatable.</li><li>Veracyte says the partnership will accelerate two key lung cancer programs, a non-invasive nasal swab test for the early detection of lung cancer and the commercialization of its Percepta classifier, expected to launch in H1.</li><li>Under the terms of the agreement, VCYT will receive $5M upfront and up to $15M in milestones. It also says that the deal should boost service revenue this year by ~$5M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420366\" data-linked=\"Veracyte teams up with J&amp;J in lung cancer; shares up 2%\" data-tweet=\"$VCYT $VCYT $JNJ - Veracyte teams up with J&amp;J in lung cancer; shares up 2% https://seekingalpha.com/news/3420366-veracyte-teams-up-j-and-j-in-lung-cancer-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3420366-veracyte-teams-up-j-and-j-in-lung-cancer-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420361\" data-ts=\"1546528000\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBS\" target=\"_blank\">CBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420361-cbs-confirms-contractual-impasse-nielsen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CBS confirms &#39;contractual impasse&#39; with Nielsen</a></h4><ul>   <li>CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color=\"red\">-0.4%</font>) has acknowledged earlier reporting about a breakdown in its relationship with ratings provider Nielsen (<a href=\"http://seekingalpha.com/symbol/NLSN\" target=\"_blank\">NLSN</a> <font color=\"red\">-0.9%</font>), saying it's at a \"<a href=\"https://www.cbscorporation.com/cbs-corporation-statement-on-nielsen-negotiations/\" target=\"_blank\">contractual impasse</a>\" on the deal.</li>    <li>\"The entire media industry is aware of the need for complete and accurate measurement across platforms,\" CBS says in its statement. \"While Nielsen has made some strides in this area, progress has not been what we and many clients would like, and local TV measurement is particularly challenged.\"</li>    <li>In spite of that, Nielsen is using market power to bundle services and raise prices, CBS says, and the network is open to \"many viable alternatives available to us, including comScore (<a href=\"http://seekingalpha.com/symbol/SCOR\" target=\"_blank\">SCOR</a> <font color=\"red\">-2.2%</font>).\"</li><li>The change in a new year brought reports that <a href=\"https://seekingalpha.com/news/3419994-cbs-ratings-contract-nielsen-lapses\" target=\"_blank\">CBS and Nielsen's deal had lapsed</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420361\" data-linked=\"CBS confirms &#39;contractual impasse&#39; with Nielsen\" data-tweet=\"$CBS $VIAC $NLSN - CBS confirms &#39;contractual impasse&#39; with Nielsen https://seekingalpha.com/news/3420361-cbs-confirms-contractual-impasse-nielsen?source=tweet\" data-url=\"https://seekingalpha.com/news/3420361-cbs-confirms-contractual-impasse-nielsen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420360\" data-ts=\"1546527903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNKN\" target=\"_blank\">DNKN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420360-coffee-shop-divergence-dunkinplus-4-starbucksminus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coffee shop divergence: Dunkin&#39; +4%, Starbucks -3%</a></h4><ul> <li>Dunkin' Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/DNKN' title='Dunkin&#39; Brands'>DNKN</a>) shoots <font color=\"green\">up 3.8%</font> in early trading.</li> <li>There isn't any new announcements from the company or M&amp;A developments, but interestingly the DNKN rally is coinciding with a <font color=\"red\">3.4% drop</font> in Starbucks (NASDAQ:<a href='https://seekingalpha.com/symbol/SBUX' title='Starbucks Corporation'>SBUX</a>) on China concerns. It's possible that some investors are taking refuge in DNKN due to the high mix of U.S. locations for the Dunkin' Donuts chain.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3420360\" data-linked=\"Coffee shop divergence: Dunkin&#39; +4%, Starbucks -3%\" data-tweet=\"$DNKN $DNKN $SBUX - Coffee shop divergence: Dunkin&#39; +4%, Starbucks -3% https://seekingalpha.com/news/3420360-coffee-shop-divergence-dunkinplus-4-starbucksminus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3420360-coffee-shop-divergence-dunkinplus-4-starbucksminus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420357\" data-ts=\"1546527662\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COCP\" target=\"_blank\">COCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420357-cocrystal-pharma-up-11-on-merck-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cocrystal Pharma up 11% on Merck collaboration</a></h4><ul><li>Thinly traded micro cap Cocrystal Pharma (<a href='https://seekingalpha.com/symbol/COCP' title='Cocrystal Pharma, Inc.'>COCP</a> <font color=\"green\">+11.1%</font>) is up on almost a 10x surge in volume, albeit on turnover of only 411K shares, in response to its license and <a href=\"https://seekingalpha.com/pr/17369497-cocrystal-pharma-announces-exclusive-worldwide-license-collaboration-agreement-merck\" target=\"_blank\">collaboration </a>deal with Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color=\"red\">-0.6%</font>) aimed at discovering and developing antiviral therapies for influenza, hepatitis C and noroviruses.</li><li>Under the terms of the partnership, MRK will fund R&amp;D, including clinical development, and will be responsible for global commercialization of all products. COCP will receive an undisclosed upfront payment, up to $156M in milestones and royalties on net sales.</li><li>COCP's lead program is CC-42344 for influenza strain A.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420357\" data-linked=\"Cocrystal Pharma up 11% on Merck collaboration\" data-tweet=\"$COCP $COCP $MRK - Cocrystal Pharma up 11% on Merck collaboration https://seekingalpha.com/news/3420357-cocrystal-pharma-up-11-on-merck-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3420357-cocrystal-pharma-up-11-on-merck-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420349\" data-ts=\"1546527200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TM\" target=\"_blank\">TM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420349-toyota-motor-u-s-sales-down-0_9-in-december\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toyota Motor U.S. sales down 0.9% in December</a></h4><ul><li><p>Toyota (<a href='https://seekingalpha.com/symbol/TM' title='Toyota Motor Corporation'>TM</a> <font color='red'>-0.2%</font>) unit sales <a href=\"https://seekingalpha.com/pr/17369683-toyota-motor-north-america-reports-december-2018-year-end-sales\" sasource=\"qp_sum_news_13\" target=\"_blank\">-0.9%</a> to 220,910 units in December vs. -1.3% forecast by Edmunds.</p></li><li><p>Toyota division sales dropped 1.1% to 185,386 units.</p></li><li><p>Lexus division sales up 0.2% to 35,524 units.</p></li><li><p>Total YARIS sales squeezed 40.7% to 1,252 units.</p></li><li><p>Camry sales fell 32.9% and Corolla sales up 27.4%.</p></li><li><p>Prius sales slipped 33% to 6,351 units for the month.</p></li><li><p>On the SUV front, RAV4 sales +18.8%, Highlander sales +9.9% and Land Cruiser -54.1%.</p></li><li><p>YTD Toyota U.S. sales down 0.3% to 2,426,672 units</p></li></ul><div class=\"tiny-share-widget\" data-id=\"3420349\" data-linked=\"Toyota Motor U.S. sales down 0.9% in December\" data-tweet=\"$TM - Toyota Motor U.S. sales down 0.9% in December https://seekingalpha.com/news/3420349-toyota-motor-u-s-sales-down-0_9-in-december?source=tweet\" data-url=\"https://seekingalpha.com/news/3420349-toyota-motor-u-s-sales-down-0_9-in-december\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420344\" data-ts=\"1546526811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MVIS\" target=\"_blank\">MVIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420344-microvision-raises-1_2m-in-stock-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MicroVision raises $1.2M in stock sale</a></h4><ul><li>MicroVision (NASDAQ:<a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a>) <a href=\"https://seekingalpha.com/pr/17369588-microvision-raises-1_2-million-sale-common-stock\" target=\"_blank\">announces</a> the sale of 2M shares of common stock at $0.60 per share in a direct offering for gross proceeds of $1.2M.</li><li>MicroVision shares are <font color=\"green\">up 5.7%</font> to $0.74.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420344\" data-linked=\"MicroVision raises $1.2M in stock sale\" data-tweet=\"$MVIS - MicroVision raises $1.2M in stock sale https://seekingalpha.com/news/3420344-microvision-raises-1_2m-in-stock-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3420344-microvision-raises-1_2m-in-stock-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420338\" data-ts=\"1546526400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420338-sohu-baidu-lower-after-chinese-suspension-over-vulgar-content\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sohu, Baidu lower after Chinese suspension over vulgar content</a></h4><ul>   <li>Shares in Sohu.com (NASDAQ:<a href='https://seekingalpha.com/symbol/SOHU' title='Sohu.com Inc.'>SOHU</a>) are <font color=\"red\">down 3.6%</font> out of Nasdaq's open after China today suspended the company's news channel for a week, telling it to rectify \"vulgar information\" in the product.</li>    <li>Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) is <font color=\"red\">off 1.9%</font> on a similar suspension. China's Internet regulator announced the moves on its WeChat account.</li>    <li>Sohu and Baidu were called to meet by Chinese regulators Wednesday, and each company says it will meet the requirements.</li><li>Source: Bloomberg</li>    <li>Other Chinese content providers on the move today: <a href='https://seekingalpha.com/symbol/YY' title='YY Inc.'>YY</a> <font color=\"red\">-2%</font>; <a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a> <font color=\"red\">-1.3%</font>; <a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a> <font color=\"red\">-2.9%</font> (and <a href='https://seekingalpha.com/symbol/SINA' title='Sina Corporation'>SINA</a> <font color=\"red\">-1.5%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420338\" data-linked=\"Sohu, Baidu lower after Chinese suspension over vulgar content\" data-tweet=\"$BIDU $SOHU $BIDU - Sohu, Baidu lower after Chinese suspension over vulgar content https://seekingalpha.com/news/3420338-sohu-baidu-lower-after-chinese-suspension-over-vulgar-content?source=tweet\" data-url=\"https://seekingalpha.com/news/3420338-sohu-baidu-lower-after-chinese-suspension-over-vulgar-content\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420337\" data-ts=\"1546526387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420337-stocks-down-1-open\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks down more than 1% at open</a></h4><ul><li>Futures got a bit of the boost off of their worst levels after Dallas Fed President told Bloomberg <a href=\"https://seekingalpha.com/news/3420274-feds-kaplan-calls-pause-interest-rate-hikes\" target=\"_blank\">he's in favor of </a>a pause in the rate-hike cycle.</li><li>In early action, the S&amp;P 500 is <font color=\"red\">down \"only\" 1%</font> and the Nasdaq <font color=\"red\">1.3%</font>. Apple is <font color=\"red\">off 9.25%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420337\" data-linked=\"Stocks down more than 1% at open\" data-tweet=\"Stocks down more than 1% at open https://seekingalpha.com/news/3420337-stocks-down-1-open?source=tweet\" data-url=\"https://seekingalpha.com/news/3420337-stocks-down-1-open\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420322\" data-ts=\"1546525458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LL\" target=\"_blank\">LL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420322-lumber-liquidatorsminus-4-after-loop-tosses-bullish-thesis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lumber Liquidators -4% after Loop tosses bullish thesis</a></h4><ul> <li>Lumber Liquidators (NYSE:<a href='https://seekingalpha.com/symbol/LL' title='Lumber Liquidators Holdings, Inc.'>LL</a>) stumbles in early trading after Loop Capital downgrades the company to a Hold rating from Buy. A warning on the impact of heightened promotional activity on Lumber Liquidators' margins is sounded by the Loop analyst team.</li> <li>The firm chops the price target on LL all the way to $10 from $24 in a capitulation of its bullish thesis. Notably, Loop was the last firm standing with a positive rating on Lumber Liquidators.</li> <li>Shares of Lumber Liquidators are <font color=\"red\">down 4.01%</font> in premarket trading to $9.57. The 52-week low for LL is $9.35.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420322\" data-linked=\"Lumber Liquidators -4% after Loop tosses bullish thesis\" data-tweet=\"$LL - Lumber Liquidators -4% after Loop tosses bullish thesis https://seekingalpha.com/news/3420322-lumber-liquidatorsminus-4-after-loop-tosses-bullish-thesis?source=tweet\" data-url=\"https://seekingalpha.com/news/3420322-lumber-liquidatorsminus-4-after-loop-tosses-bullish-thesis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420317\" data-ts=\"1546525195\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COCP\" target=\"_blank\">COCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420317-cocp-celg-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">COCP, CELG among premarket gainers</a></h4><ul><li>Cocrystal Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/COCP' title='Cocrystal Pharma, Inc.'>COCP</a>) <font color=\"green\">+43%</font> on <a href=\"https://seekingalpha.com/pr/17369497-cocrystal-pharma-announces-exclusive-worldwide-license-collaboration-agreement-merck\" target=\"_blank\">entering</a> into an exclusive license and collaboration agreement with Merck to discover and develop certain proprietary influenza A/B antiviral agents.</li><li>Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) <font color=\"green\">+34%</font> on being <a href=\"https://seekingalpha.com/news/3420229-bristol-myers-squibb-acquire-celgene-74b\" target=\"_blank\">acquired</a> by Bristol-Myers.</li><li>Alliqua BioMedical (NASDAQ:<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a>) <font color=\"green\">+27%</font> on <a href=\"https://seekingalpha.com/news/3420265-alliqua-biomedical-provides-update-shareholders-shares-23-percent-premarket\" target=\"_blank\">update</a>.</li><li>IZEA Worldwide (NASDAQ:<a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a>) <font color=\"green\">+23%</font> on December <a href=\"https://seekingalpha.com/news/3420171-izea-plus-25-percent-december-contract-wins\" target=\"_blank\">contract wins</a>.</li><li>DBV Technologies S.A. (NASDAQ:<a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/news/3420227-dbv-technologies-expands-leadership-team-shares-14-percent-premarket\" target=\"_blank\">expanding</a> leadership team.</li><li>Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP (NYSE:<a href='https://seekingalpha.com/symbol/SBS' title='Companhia de Saneamento Basico do Estado de Sao Paulo-SABESP'>SBS</a>) <font color=\"green\">+14%</font>.</li><li>Centrais Eletricas Brasileiras S.A. - Eletrobras (NYSE:<a href='https://seekingalpha.com/symbol/EBR' title='Centrais Eletricas Brasileiras S.A. - Eletrobras'>EBR</a>) <font color=\"green\">+8%</font>.</li><li>Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/pr/17369238-moleculin-announces-positive-data-pancreatic-cancer-drug-candidate\" target=\"_blank\">positive</a> data for its pancreatic cancer drug candidate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420317\" data-linked=\"COCP, CELG among premarket gainers\" data-tweet=\"$COCP $COCP $CELG - COCP, CELG among premarket gainers https://seekingalpha.com/news/3420317-cocp-celg-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420317-cocp-celg-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420312\" data-ts=\"1546524858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SESN\" target=\"_blank\">SESN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420312-aapl-stm-and-bmy-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AAPL, STM and BMY among premarket losers</a></h4><ul><li>Sesen Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SESN' title='Sesen Bio, Inc.'>SESN</a>) <font color=\"red\">-28%</font> on late-stage <a href=\"https://seekingalpha.com/news/3420273-sesen-bio-22-percent-premarket-late-stage-vicinium-data\" target=\"_blank\">Vicinium data</a>.</li><li>Prana Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/PRAN' title='Prana Biotechnology Ltd'>PRAN</a>) <font color=\"red\">-11%</font>.</li><li>Mellanox Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>) <font color=\"red\">-9%</font> <a href=\"https://seekingalpha.com/news/3420293-mellanox-tech-appoints-cfo\" target=\"_blank\">following</a> Apple's Q1 revenue warning.</li><li>Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) <font color=\"red\">-9%</font> on announcing <a href=\"https://seekingalpha.com/news/3420157-apple-cuts-q1-revenue-guidance\" target=\"_blank\">cut</a> in Q1 revenue guidance.</li><li>Lumentum Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) <font color=\"red\">-9%</font> <a href=\"https://seekingalpha.com/news/3420293-mellanox-tech-appoints-cfo\" target=\"_blank\">following</a> Apple's Q1 revenue warning.</li><li>STMicroelectronics (NYSE:<a href='https://seekingalpha.com/symbol/STM' title='STMicroelectronics NV'>STM</a>) <font color=\"red\">-8%</font> <a href=\"https://seekingalpha.com/news/3420293-mellanox-tech-appoints-cfo\" target=\"_blank\">following</a> Apple's Q1 revenue warning.</li><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3420229-bristol-myers-squibb-acquire-celgene-74b\" target=\"_blank\">acquiring</a> Celgene for $74B.</li><li>China Ceramics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a>) <font color=\"red\">-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420312\" data-linked=\"AAPL, STM and BMY among premarket losers\" data-tweet=\"$SESN $SESN $ATHE - AAPL, STM and BMY among premarket losers https://seekingalpha.com/news/3420312-aapl-stm-and-bmy-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3420312-aapl-stm-and-bmy-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420310\" data-ts=\"1546524782\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMR\" target=\"_blank\">IMMR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420310-immersionplus-11_6-on-google-haptics-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immersion +11.6% on Google haptics deal</a></h4><ul><li>Immersion (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMR' title='Immersion Corporation'>IMMR</a>) <a href=\"https://seekingalpha.com/pr/17369448-immersion-enters-agreement-google-development-next-generation-haptic-devices\" target=\"_blank\">announces</a> a multi-year agreement with Google (NASDAQ:<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) to explore opportunities to incorporate haptics in Google's next-gen hardware products.</li><li>The agreement also gives Google a license to Immersion's IP for the Pixel line and other hardware.</li><li>Other terms of the deal weren't disclosed.</li><li>Immersion shares are <font color=\"green\">up 11.6%</font> premarket to $10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420310\" data-linked=\"Immersion +11.6% on Google haptics deal\" data-tweet=\"$IMMR $IMMR $GOOGL - Immersion +11.6% on Google haptics deal https://seekingalpha.com/news/3420310-immersionplus-11_6-on-google-haptics-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3420310-immersionplus-11_6-on-google-haptics-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420308\" data-ts=\"1546524651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTAI\" target=\"_blank\">BTAI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420308-bioxcel-up-20-premarket-of-positive-dexmedetomidine-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioXcel up 20% premarket of positive dexmedetomidine data</a></h4><ul><li>Thinly traded nano cap BioXcel Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BTAI' title='BioXcel Therapeutics'>BTAI</a>) is up <font color=\"green\">20% </font>premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17369280-bioxcel-therapeutics-reports-positive-human-proof-concept-data-acute-treatment-agitation\" target=\"_blank\">announcement </a>of Phase 1 data on IV dexmedetomidine (Dex) for the treatment of agitation in patients with Senile Dementia of the Alzheimer's Type &#40;SDAT&#41;.</li><li>70% (n=7/10) of treated patients achieved arousal sedation (-1 score on a scale called RASS) compared to 25% (n=1/4) for placebo. The drug was well-tolerated and a safe dose was identified.</li><li>The company says the positive outcome supports the rationale for Fast Track-tagged BXCL501, a sublingual formulation of dexmedetomidine. Top-line data from a a Phase 1 dose-escalation pharmacokinetic study should be available in H1.</li><li>Management will host a conference call at 11:30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420308\" data-linked=\"BioXcel up 20% premarket of positive dexmedetomidine data\" data-tweet=\"$BTAI - BioXcel up 20% premarket of positive dexmedetomidine data https://seekingalpha.com/news/3420308-bioxcel-up-20-premarket-of-positive-dexmedetomidine-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3420308-bioxcel-up-20-premarket-of-positive-dexmedetomidine-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420303\" data-ts=\"1546524266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXPE\" target=\"_blank\">EXPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420303-online-travel-players-eye-marriott-expedia-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Online travel players eye Marriott-Expedia talks</a></h4><ul> <li>There's a potentially big development going on in the online travel sector, according to Bloomberg.</li><li>Telsey Advisory analyst Brian McGill says Expedia (NASDAQ:<a href='https://seekingalpha.com/symbol/EXPE' title='Expedia, Inc.'>EXPE</a>) and Marriott International (NYSE:<a href='https://seekingalpha.com/symbol/MAR' title='Marriott International, Inc.'>MAR</a>) are negotiating out a new commission rate that could lead to discussions with other hotel operators.</li> <li>Of concern to the online travel players, Marriott went into the talks with a bit more leverage since it acquired Starwood. \"Bad news is that this would now incentivize the other branded hotels to push for take rates below the current 12% to 14% range,\" warns McGill. The development is worth watching for shareholders of Booking Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BKNG' title='Booking Holdings Inc.'>BKNG</a>), TripAdvisor (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIP' title='TripAdvisor Inc.'>TRIP</a>) and Trivago (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVG' title='Trivago'>TRVG</a>),</li> <li>EXPE <font color=\"red\">-0.92%</font> premarket to $110.95. TRIP <font color=\"red\">-1.88%</font> to $53.20. BKNG <font color=\"red\">-1.36%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420303\" data-linked=\"Online travel players eye Marriott-Expedia talks\" data-tweet=\"$EXPE $EXPE $MAR - Online travel players eye Marriott-Expedia talks https://seekingalpha.com/news/3420303-online-travel-players-eye-marriott-expedia-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3420303-online-travel-players-eye-marriott-expedia-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420288\" data-ts=\"1546522959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHI\" target=\"_blank\">RHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420288-bank-of-america-merrill-lynch-cools-on-robert-half\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of America Merrill Lynch cools on Robert Half</a></h4><ul> <li>Bank of America Merrill Lynch downgrades Robert Half International (NYSE:<a href='https://seekingalpha.com/symbol/RHI' title='Robert Half International Inc.'>RHI</a>) to a Neutral rating after factoring in thr recent revenue deceleration.</li> <li>\"We believe cyclical concerns and tougher comps will make it difficult for the stock to outperform in the near-term,\" warns the firm. \"While we expect RHI to deliver solid growth in 2019 if the US economy grows 2% or better, revenue growth is likely to decelerate in the next few quarters as RHI faces sharply more difficult comps,\" adds the BAML analyst team.</li> <li>BAML drops it price objective to $63 (16X the 2019 EPS estimate).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3420288\" data-linked=\"Bank of America Merrill Lynch cools on Robert Half\" data-tweet=\"$RHI - Bank of America Merrill Lynch cools on Robert Half https://seekingalpha.com/news/3420288-bank-of-america-merrill-lynch-cools-on-robert-half?source=tweet\" data-url=\"https://seekingalpha.com/news/3420288-bank-of-america-merrill-lynch-cools-on-robert-half\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420287\" data-ts=\"1546522953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOV\" target=\"_blank\">KTOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420287-kitovplus-40-on-signing-marketing-agreement-coeptis-pharmaceuticals-for-consensi\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kitov +40% on signing marketing agreement with Coeptis Pharmaceuticals for Consensi</a></h4><ul> <li>Kitov Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a>) has <a href=\"https://seekingalpha.com/pr/17369223-kitov-signs-marketing-distribution-agreement-lead-product-consensi-u-s-coeptis\" target=\"_blank\">signed</a> an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. market. Coeptis will commercialize Kitov\u2019s combination drug, Consensi, intended to simultaneously treat osteoarthritis pain and hypertension.</li>             <li>The agreement provides for total milestone payments from Coeptis to Kitov of $3.5M. In addition, Kitov will be paid 40%-60% of Coeptis\u2019 net profit on Consensi sales. The agreement is for a term of fifteen years and may be extended for additional two-year terms.</li>      <li>Consensi, under patent protection in the U.S. until 2030, is expected to be launched during 2019.</li><li>Shares are up <font color=\"green\">40%</font> premarket.</li>                  </ul><div class=\"tiny-share-widget\" data-id=\"3420287\" data-linked=\"Kitov +40% on signing marketing agreement with Coeptis Pharmaceuticals for Consensi\" data-tweet=\"$KTOV - Kitov +40% on signing marketing agreement with Coeptis Pharmaceuticals for Consensi https://seekingalpha.com/news/3420287-kitovplus-40-on-signing-marketing-agreement-coeptis-pharmaceuticals-for-consensi?source=tweet\" data-url=\"https://seekingalpha.com/news/3420287-kitovplus-40-on-signing-marketing-agreement-coeptis-pharmaceuticals-for-consensi\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420280\" data-ts=\"1546522115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420280-canadian-solar-to-provide-epc-solar-modules-for-australian-solar-farm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Solar to provide EPC, solar modules for Australian solar farm</a></h4><ul><li>Canadian Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a>) says it will partner with Signal Energy to provide engineering, procurement and construction services and <a href=\"https://seekingalpha.com/pr/17369155-canadian-solar-provide-epc-services-supply-solar-modules-175-mwp-finley-solar-farm-australia\" target=\"_blank\">supply solar modules</a> for ESCO Pacific's Finley Solar Farm in Australia; financial terms are not disclosed.</li><li>CSIQ says the solar plant will produce enough electricity to meet the needs of more than 90K homes in New South Wales and displace 400K metric tons/year of carbon dioxide emissions.</li><li>CSIQ expects construction of the project will be completed in October 2019.</li><li>CSIQ <font color=\"green\">+4.6%</font> pre-market after Goldman Sachs <a href=\"https://seekingalpha.com/news/3420238-first-solar-canadian-solar-upgraded-buy-goldman-sachs\" target=\"_blank\">upgraded</a> shares to Buy from Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420280\" data-linked=\"Canadian Solar to provide EPC, solar modules for Australian solar farm\" data-tweet=\"$CSIQ - Canadian Solar to provide EPC, solar modules for Australian solar farm https://seekingalpha.com/news/3420280-canadian-solar-to-provide-epc-solar-modules-for-australian-solar-farm?source=tweet\" data-url=\"https://seekingalpha.com/news/3420280-canadian-solar-to-provide-epc-solar-modules-for-australian-solar-farm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420279\" data-ts=\"1546522106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTX\" target=\"_blank\">UTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420279-citi-resumes-united-tech-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi resumes United Tech at Neutral</a></h4><ul><li>United Technologies (NYSE:<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a>) <font color=\"red\">-1%</font> premarket after Citi analyst Jonathan Raviv resumed coverage on the stock with a Neutral rating, while lowering his PT to $120 from $125.</li><li>The largest catalyst for the decision occurred in late November, when the company announced the closure of its Rockwell Collins acquisition and the planned three-way split between Aero, Otis and Carrier.</li><li>Source: Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3420279\" data-linked=\"Citi resumes United Tech at Neutral\" data-tweet=\"$UTX - Citi resumes United Tech at Neutral https://seekingalpha.com/news/3420279-citi-resumes-united-tech-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3420279-citi-resumes-united-tech-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420278\" data-ts=\"1546522011\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420278-tesla-lower-china-news-in-mix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla lower with China news in the mix</a></h4><ul> <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) falls in early trading as Apple's downturn in sales in China adds another level of anxiety over the Chinese economy and spillover from the U.S. trade war for companies selling in the region.</li><li><em>The Financial Times</em> is also out with a cautionary article on Tesla to start the year after digesting the EV automaker's reduction in prices across models. \"Cut prices much further, however, and Tesla could find itself trapped in the same low-margin position as other big producers \u2014 with a stock market valuation to match,\" warns <em>FT</em>.</li><li>More from <em>FT</em>: \"Production costs should decline as volumes rise and Tesla works out cheaper ways to make its vehicles. But finding sufficient savings to bring down the sticker price while also making up for the lost tax incentives will be a stretch.\"</li> <li>TSLA <font color=\"red\">-1.67%</font> premarket to $304.95 after shedding 6.82% yesterday following the company's update on deliveries.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3420278\" data-linked=\"Tesla lower with China news in the mix\" data-tweet=\"$TSLA - Tesla lower with China news in the mix https://seekingalpha.com/news/3420278-tesla-lower-china-news-in-mix?source=tweet\" data-url=\"https://seekingalpha.com/news/3420278-tesla-lower-china-news-in-mix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420277\" data-ts=\"1546522008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLRX\" target=\"_blank\">VLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420277-valeritas-v-go-preferred-on-humana-part-d-formularies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeritas&#39; V-Go preferred on Humana Part D formularies</a></h4><ul> <li>Valeritas Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>) <a href=\"https://seekingalpha.com/pr/17369221-valeritas-announces-v-go-preferred-humana-part-d-formularies\" target=\"_blank\">announces</a> that Humana has given V-Go Preferred status on its Part D formularies.</li>   <li>This will improve patient access to V-Go at an affordable monthly copay for members with type 2 diabetes.</li>  <li>V-Go is available as Preferred on Humana\u2019s Part D formularies, which include their MAPD and Enhanced PDP formularies.</li><li>Shares are up <font color=\"green\">12%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3420277\" data-linked=\"Valeritas&#39; V-Go preferred on Humana Part D formularies\" data-tweet=\"$VLRX - Valeritas&#39; V-Go preferred on Humana Part D formularies https://seekingalpha.com/news/3420277-valeritas-v-go-preferred-on-humana-part-d-formularies?source=tweet\" data-url=\"https://seekingalpha.com/news/3420277-valeritas-v-go-preferred-on-humana-part-d-formularies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420272\" data-ts=\"1546521419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420272-teva-settles-cinacalcet-patent-dispute-amgen-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva settles cinacalcet patent dispute with Amgen; shares up 3% premarket</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) is up <font color=\"green\">3%</font> premarket on average volume in response to the <a href=\"https://seekingalpha.com/pr/17369040-teva-amgen-resolve-ongoing-dispute-teva-s-generic-cinacalet-hcl-product\" target=\"_blank\">settlement</a> of its patent infringement litigation with Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) related to its generic version of Sensipar (cinacalcet).</li><li>Under the terms of the settlement, TEVA has agreed to stop selling its generic product until mid-2021 or earlier under certain circumstances. It will also pay AMGN an undisclosed amount. Other terms are confidential.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420272\" data-linked=\"Teva settles cinacalcet patent dispute with Amgen; shares up 3% premarket\" data-tweet=\"$TEVA $TEVA $AMGN - Teva settles cinacalcet patent dispute with Amgen; shares up 3% premarket https://seekingalpha.com/news/3420272-teva-settles-cinacalcet-patent-dispute-amgen-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3420272-teva-settles-cinacalcet-patent-dispute-amgen-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420268\" data-ts=\"1546521202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNF\" target=\"_blank\">UNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420268-on-unifirsts-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on UniFirst&#39;s Q1</a></h4><ul><li>Unifirst (NYSE:<a href='https://seekingalpha.com/symbol/UNF' title='UniFirst Corp.'>UNF</a>) reports Core Laundry revenue rose 4.5% to $390.48M in <a href=\"https://seekingalpha.com/pr/17369393-unifirst-announces-financial-results-first-quarter-fiscal-2019-board-directors-authorizes\" target=\"_blank\">Q1</a>.</li><li>Specialty Garments segment revenue grew 21.2% to $34.45M</li><li>First Aid segment revenue up 0.5% to $13.63M.</li><li>Gross margin rate declined 222 bps to 38.16%.</li><li>Operating margin rate slipped 100 bps to 11.5%.</li><li>Segment earnings: Core Laundry operations: $44.78M (-3.4%); Specialty Garment: $4.47M (-0.2%); First Aid: $1.17M (+9.1%).</li><li><b>FY2019 Guidance</b>: Revenues: $1.765B to $1.785B; Diluted EPS: $6.65 to $6.95.</li><li>The Board of Directors authorized the Company to repurchase up to $100M of its outstanding shares of common stock.</li><li>UNF <font color=\"red\">-0.74%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3420264-unifirst-misses-0_04-beats-revenue\" target=\"_blank\">UniFirst misses by $0.04, beats on revenue</a> (Jan. 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3420268\" data-linked=\"More on UniFirst&#39;s Q1\" data-tweet=\"$UNF - More on UniFirst&#39;s Q1 https://seekingalpha.com/news/3420268-on-unifirsts-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3420268-on-unifirsts-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420265\" data-ts=\"1546520834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALQA\" target=\"_blank\">ALQA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420265-alliqua-biomedical-provides-update-to-shareholders-shares-up-23-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alliqua Biomedical provides update to shareholders; shares up 23% premarket</a></h4><ul> <li>Alliqua Biomedical (NASDAQ:<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a>) <a href=\"https://seekingalpha.com/pr/17369200-alliqua-biomedical-ceo-provides-update-shareholders\" target=\"_blank\">provides</a> following updates to shareholders:</li>         <li>The Company completed sale of asset and rights relating to UltraMist Therapy System on May 7, 2018 to Celularity Inc.</li>    <li>On October 11, 2018, the Company signed merger agreement with Adynxx, Inc. The transaction is expected to close in Q1 2019.</li>    <li>On November 28, 2018, Alliqua announced to spin off its contract-manufacturing subsidiary Aquamed Technologies, and merge the business with TO Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TGLP' title='Tongli Pharmaceuticals &#40;USA&#41;, Inc.'>OTCPK:TGLP</a>) to establish a clinical-stage pharmaceutical company focused on commercializing cannabinoid-based therapies. The transaction will close in Q1 2019.</li>    <li>The company also intends to pay a special dividend in the range of $1.00 to $1.20 per share.</li><li>Shares are up <font color=\"green\">23%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3420265\" data-linked=\"Alliqua Biomedical provides update to shareholders; shares up 23% premarket\" data-tweet=\"$ALQA $ADYX $TGLP - Alliqua Biomedical provides update to shareholders; shares up 23% premarket https://seekingalpha.com/news/3420265-alliqua-biomedical-provides-update-to-shareholders-shares-up-23-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3420265-alliqua-biomedical-provides-update-to-shareholders-shares-up-23-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420255\" data-ts=\"1546520367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMM\" target=\"_blank\">MMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420255-credit-suisse-weighs-in-on-industrials\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse weighs in on industrials</a></h4><ul><li>3M (NYSE:<a href='https://seekingalpha.com/symbol/MMM' title='3M Company'>MMM</a>) <font color=\"red\">-1.5%</font> premarket after analyst John Walsh lowered his price target on the stock to $220 from $230, reflecting a reduction in  expectations for global industrial production, energy capital expenditures and forex rates.</li><li>Emerson (NYSE:<a href='https://seekingalpha.com/symbol/EMR' title='Emerson Electric Co.'>EMR</a>) <font color=\"green\">+0.8%</font> premarket after landing an upgrade to Outperform from Neutral on expectations for an oil price recovery, strong E&amp;C backlogs and positive free cash flow generation.</li><li>Eaton (NYSE:<a href='https://seekingalpha.com/symbol/ETN' title='Eaton Corp. plc'>ETN</a>) <font color=\"red\">dropped nearly 1%</font> after Credit Suisse lowered its PT on the stock to $80 from $85, while Honeywell (NYSE:<a href='https://seekingalpha.com/symbol/HON' title='Honeywell International, Inc.'>HON</a>) is <font color=\"green\">up 0.2%</font> after snagging an upgrade to Outperform from Neutral, with a $158 price target.</li><li>The price target of Rockwell Automation (NYSE:<a href='https://seekingalpha.com/symbol/ROK' title='Rockwell Automation, Inc.'>ROK</a>) was also dropped to $158 from $170, and the PT of Flowserve (NYSE:<a href='https://seekingalpha.com/symbol/FLS' title='Flowserve Corporation'>FLS</a>) was lowered to $42 from $48.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420255\" data-linked=\"Credit Suisse weighs in on industrials\" data-tweet=\"$MMM $MMM $EMR - Credit Suisse weighs in on industrials https://seekingalpha.com/news/3420255-credit-suisse-weighs-in-on-industrials?source=tweet\" data-url=\"https://seekingalpha.com/news/3420255-credit-suisse-weighs-in-on-industrials\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3420249\" data-ts=\"1546519882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3420249-bmy-celgene-tie-up-buoys-gilead-and-vertex-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BMY/Celgene tie-up buoys Gilead and Vertex premarket</a></h4><ul><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) is up <font color=\"green\">3%</font> and Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) is up <font color=\"green\">1% </font>premarket, albeit both on modest volume, on the heels of Bristol-Myers Squibb's $74B bid for fellow biotech Celgene.</li></ul><div class=\"tiny-share-widget\" data-id=\"3420249\" data-linked=\"BMY/Celgene tie-up buoys Gilead and Vertex premarket\" data-tweet=\"$GILD $GILD $VRTX - BMY/Celgene tie-up buoys Gilead and Vertex premarket https://seekingalpha.com/news/3420249-bmy-celgene-tie-up-buoys-gilead-and-vertex-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3420249-bmy-celgene-tie-up-buoys-gilead-and-vertex-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}